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Introduction
The Polish Society of Hypertension (PTNT) presents a new edition — fifth over the last 16 
years — of its guidelines for the management of hypertension, the most common disease 
in Poland.
During four years that have passed since publication of the previous 2015 guidelines, 
results of multiple important studies and metaanalyses evaluating antihypertensive therapy 
have been published. These results have extended the range of available information, lead-
ing to modification of some concepts in the management of hypertension, in particular 
regarding optimal target blood pressure values, treatment intensity, strategies to improve 
adherence, approach to the treatment of resistant and secondary hypertension, including 
interventional treatment, and non-blood pressure lowering therapy to reduce cardiovascular 
risk.
The present document is generally based on the 2015 PTNT guidelines, retaining its 
practical nature with consideration of specific aspects of the diagnosis and drug treatment 
of hypertension in Poland, but it also includes some new teaching concepts and most of the 
changes, which were considered appropriate by the authors of the present guidelines, that 
were introduced in the most recent 2018 European Society of Cardiology/European Society 
of Hypertension (ESC/ESH) guidelines.
Instead of typical recommendation grading (including classes of recommendations and 
levels of evidence), a traffic light signalling system-based classification has been retained in 
the tables summarising the basic principles of the management of hypertension, reflecting 
not only available evidence but also expert opinion to a greater degree compared to the 
2018 ESC/ESH guidelines.
These colours mean:
green — a given management approach is recommended, generally based on clear 
evidence from research studies, or unequivocal expert opinion reflecting current 
clinical practice
yellow — a given management approach is suggested as appropriate despite weaker 
supporting data due to lacking or equivocal evidence from research studies, based 
on the opinion of the majority of experts reflecting common sense and their per-
sonal clinical experience
red — a given management approach should be abandoned as it is considered not 
justified or harmful, generally based on clear evidence from research studies or the 
opinion of the majority of experts
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1. Epidemiology and prevention 
of hypertension
Hypertension remains the most important modifi-
able cardiovascular risk factor, and according to the 
World Health Organisation, it is also most com-
mon cause of premature mortality worldwide. Blood 
pressure (BP) values show a linear correlation with 
mortality and the incidence of cardiovascular disease 
(myocardial infarction, stroke, peripheral arterial dis-
ease) and chronic kidney disease in all age and ethnic 
groups in both women and men. Among subjects 
above 50 years of age, systolic blood pressure (SBP) 
is a better indicator of cardiovascular risk, and pulse 
pressure or the difference between SBP and diastolic 
blood pressure (DBP) is an additional marker of an 
increased risk.
Data obtained during the last 20 years indicate 
an increasing prevalence of hypertension in Poland. 
The NATPOL 2011 study showed that over 10 years, 
the prevalence of hypertension in individuals aged 
18–79 years increased from 30% to 32% or 9.5 
million people, based on BP measurements during 
two separate visits. In addition, the POLSENIOR 
study indicates that hypertension is present in more 
than one million of people above 80 years of age. In 
the 2014 WOBASZ II study, the prevalence of el-
evated BP values in adult Poles aged 19–99 years was 
42.7%. The proportion of subjects with a previous 
diagnosis of hypertension was 59.3%, treatment was 
initiated in 46.1%, and BP was controlled in 23%. 
Considering that prevalence estimates are at least 9% 
lower when the diagnosis of hypertension is based 
on BP measurements during at least two separate 
visits, as recommended in the guidelines, compared 
to those during a single visit, the number of subjects 
with hypertension in Poland based on the NATPOL 
and WOBASZ studies can be estimated at about 11 
million. If these trends continue, it has been esti-
mated that the number of subjects with hypertension 
in Poland will have increased by half until 2035.
Development of hypertension may be best pre-
vented by interventions targeted at environmental 
factors. The most effective approach to prevent or 
delay development of hypertension (primary preven-
tion) is lifestyle modification, in particular prevent-
ing obesity and increasing physical activity. Primary 
prevention may be divided into population efforts, 
directed at the general population, and prevention 
targeted at those at an increased risk of hypertension. 
The latter, more intensive efforts should focus on the 
following groups:
1. Subjects with a family history of premature car-
diovascular disease (stroke, myocardial infarction, 
heart failure) — below 65 years of age in women 
and 55 years of age in men.
2. Patients with diabetes or concomitant kidney dis-
ease.
3. Subjects with at least two conventional cardiovas-
cular risk factors.
4. Subjects with BP ≥130/85 mm Hg.
The goal of primary prevention is to increase 
detection of hypertension, possibly in its early 
asymptomatic period when target organ damage is 
still absent or limited. Preventive efforts should also 
be targeted at those with established hypertension. 
About 30% of subjects are unaware of hypertension 
which results from the fact that nearly 40% of people 
in Poland do not know their BP values. Due to low 
hypertension detection rate in Poland, screening BP 
measurements are recommended in all adults at least 
once a year regardless of previous BP values.
Late secondary (tertiary) prevention includes 
therapeutic interventions in subjects with established 
disease to prevent or at least delay adverse sequelae 
of hypertension (cardiovascular and renal complica-
tions). Public awareness of the risks associated with 
high BP has increased but remains unsatisfactory. The 
NATPOL 2011 study showed that the proportion 
of subjects with the diagnosis of hypertension who 
remained untreated decreased from 18% to 13%.
2. Diagnosis and classification
The diagnosis of hypertension is based on prop-
erly performed office BP measurements. Due to the 
ban on the use of mercury in the European Union, 
semiautomatic auscultatory or oscillometric sphyg-
momanometers are currently recommended for BP 
measurements. Obtaining reliable BP value requires 
use of an adequately accurate device, appropriate 
patient preparation, and proper measurement tech-
nique (Tab. I). Brachial BP measurements using cer-
tified BP measurement devices are recommended 
(the list of certified BP measurement devices may 
be found at the Polish Society of Hypertension [Pol-
skie Towarzystwo Nadciśnienia Tętniczego, PTNT] 
website at www.nadcisnienietetnicze.pl/dla_lekarzy/
zalecenia_i_standardy/zalecenia_ptnt).
Hypertension may be diagnosed if average BP 
values (calculated based on at least two measure-
ments on at least two different visits) are equal to or 
higher than 140 mm Hg (SBP) and/or 90 mm Hg 
(DBP).
In patients with SBP values 140–159 mm Hg 
and DBP values 90–99 mm Hg at low to moder-
ate cardiovascular risk, the diagnosis of hyperten-
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sion should be confirmed, if possible, by ambulatory 
blood pressure monitoring (ABPM) or by home BP 
measurements (Tab. II), using different threshold 
values (Tab. III).
In patients with SBP values ≥ 180 mm Hg and/or 
DBP values ≥ 110 mm Hg, the diagnosis of hyper-
tension may be made at the first visit after excluding 
an effect of factors leading to acute BP elevation, e.g., 
anxiety, pain, or alcohol intake.
The diagnosis of hypertension may also be made 
based on data from the history or patient medical 
records [BP values or use of antihypertensive medi-
cations, presence of hypertension-mediated organ 
damage (HMOD)].
The classification of hypertension is based on of-
fice BP measurements, with three grades of severity 
and the separate subtype of isolated systolic hyper-
tension (ISH). Detailed classification of hyperten-
sion is shown in Table IV.
Blood pressure values are of major importance 
when stratifying cardiovascular risk of the patient.
2.1. Automated office blood pressure 
measurements
The technique of automated office BP measurements 
(AOBPM) is similar to that of conventional office BP 
measurements, the difference being the absence of 
medical personnel with the patient during serial mea-
surements. The device is programmed to perform 
serial BP measurements 1–3 minutes apart, starting 
with a 5 minute delay, after the nurse of the physi-
cian leaves the examination room. This approach al-
lows to reduce or eliminate the effect of stress on BP 
values (white coat effect). BP values obtained during 
AOBPM are usually lower compared to conventional 
office BP measurements (SBP by about 5–15 mm 
Hg) and comparable to home and ambulatory BP 
measurements during activity. Due to very limited 
data regarding prediction of cardiovascular events 
based on AOBPM, unclear relation to office BP val-
ues, and low use of the method, normal values and 
diagnostic thresholds have not been defined yet for 
this BP measurement approach.
Table I. Principles and proper technique of office blood pressure measurements
Equipment requirements
Validated device with an arm cuff (see www.nadcisnienietetnicze.pl/dla_lekarzy/zalecenia_i_standardy/zalecenia_ptnt)
In most patients, BP measurement should be performed using a standard size arm cuff (width 12–13 cm, length 35 cm); a larger cuff should be 
used with the patient’s arm circumference > 32 cm, and a smaller cuff with arm circumference < 24 cm
Patient preparation
Patients should refrain from drinking coffee, smoking cigarettes, and using other stimulants for at least 30 minutes before the measurement
Measurement should be performed after at least 5 minutes of rest, in a sitting position with the back supported, in a quiet room at comfortable  
ambient temperature. The arm on which BP is measured should be flexed at the elbow and loosely supported at the level of the heart.  
The upper arm should be free from any restrictive clothing
Measurement technique
When measuring using the classical (auscultatory) technique, the cuff should be inflated to 30 mm Hg above the audible sounds (palpable pulse). 
The cuff should be deflated at a rate of 2 mm Hg/s
Initially, BP should be measured on both arms, with further measurements on the arm with the higher BP reading for long-term BP monitoring  
and evaluation of the effectiveness of antihypertensive therapy
With the auscultatory technique, systolic blood pressure (SBP) is defined as the appearance of the first tone during cuff deflation — Korotkoff  
phase I, and diastolic blood pressure (DBP) is defined as the disappearance of the last tone during cuff deflation — Korotkoff phase V
BP should be calculated as the mean of 2 last measurements, the standard being at least 3 BP measurements performed 1–2 minutes apart during 
the same visit. If BP values differ between subsequent measurements (> 10 mm Hg), additional measurements should be performed
BP measurements in patients with arrhythmia (e.g., atrial fibrillation) should be performed using the auscultatory technique
At the initial evaluation, orthostatic challenge (active standing) test should be performed in all patients, with BP measurements at 1 and 3 minutes 
after standing up from the sitting position. Orthostatic hypotension is defined as SBP fall by ≥ 20 mm Hg or to < 90 mm Hg or DBP fall 
by ≥ 10 mm Hg. Active lying-to-standing test (standing up from the lying position) should be considered in the elderly, diabetic patients, 
and patients with other conditions associated with an increased risk of orthostatic hypotension. Extending orthostatic BP measurements  
to 5 minutes should be considered in these groups
Pulse rate should be measured to exclude significant arrhythmia. Resting heart rate is also used for cardiovascular risk evaluation
If a BP difference is found between the arms, the higher value should be taken as actual BP (preferred simultaneous BP measurement, and if not 
available — sequential BP measurement)
BP — blood pressure; DBP — diastolic blood pressure; SBP — systolic blood pressure
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2.2. Out-of-office blood pressure 
measurements
Out-of-office BP measurements are used for the di-
agnosis of hypertension and to monitor the effects of 
antihypertensive therapy. Information obtained from 
ABPM and home BP measurements (HBPM) should 
be considered complementary. By comparing office 
and out-of-office BP measurements, it is possible to 
define phenotypes that cannot be identified based 
on conventional office BP measurements only (i.e., 
white coat hypertension, white coat effect, masked 
hypertension, or masked uncontrolled hypertension).
2.2.1 Home blood pressure measurements
Home BP measurements not only reduce the risk of 
a white-coat effect, often observed during office BP 
measurements, but also show good agreement with 
daytime ABPM measurements. In addition, home 
BP values correlate with cardiovascular risk better 
than office BP values. In the diagnosis of hyperten-
sion abnormal home BP values are defined as the 
average of several measurements greater than or equal 
to 135 and/or 85 mm Hg.
Daily home BP measurements should be advised 
particularly during the week prior to a follow-up 
Table II. Recommendations regarding home blood pressure measurements
Fully automated devices with an arm cuff are recommended (see www.nadcisnienietetnicze.pl/dla_lekarzy/zalecenia_i_standardy/zalecenia_ptnt)
Measurements should be performed during 6-7 subsequent days before the visit (minimum 3 days)
Two BP measurements should be performed several minutes apart in the morning and in the evening, at constant times of the day 
(e.g., 6.00 AM–6.00 PM, 7.00 AM–7.00 PM). Measurements should be performed before drug intake and before meals
Measurements should be performed according to the principles described in Table I
The patient should record BP values measured in a diary
For calculation of the mean BP for HBPM, values obtained during the first day should be discarded
Purposefulness of HBPM should be considered in patients with an elevated level of anxiety
Home BP values should not be used for self-modifications of the therapy by the patient
BP — blood pressure; HBPM — home blood pressure monitoring
Table III. Diagnosis of hypertension based on office and out-of-office blood pressure measurements
Category SBP [mm Hg] DBP [mm Hg]
Office BP measurements ≥ 140 and/or ≥ 90
Ambulatory BP measurements
— daytime (or awake) mean ≥ 135 and/or ≥ 85
— night-time (or sleep) mean ≥ 120 and/or ≥ 70
— mean 24-hour ≥ 130 and/or ≥ 80
Home BP measurements (mean from at least 3 days) ≥ 135 and/or ≥ 85
P — blood pressure; DBP — diastolic blood pressure; SBP — systolic blood pressure
Table IV. Definitions and classification of office blood pressure levels. Grades of hypertension apply only to office blood pressure measure-
ments
Category SBP [mm Hg] DBP [mm Hg]
Optimal BP < 120 and < 80
Normal BP 120–129 and/or 80–84
High normal BP 130–139 and/or 85–89
Grade 1 hypertension 140–149 and/or 90–99
Grade 2 hypertension 160–179 and/or 100–109
Grade 3 hypertension ≥ 180 and/or ≥ 110
Isolated systolic hypertension ≥ 140 and < 90
BP — blood pressure; DBP — diastolic blood pressure; SBP — systolic blood pressure
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visit, serving as a basis for medication adjustments 
by a physician.
Blood pressure self-measurement is relatively easy 
for the patient and may contribute to improved 
compliance and treatment effectiveness by engaging 
the patient in the therapeutic process. Prerequisites 
include teaching the patient proper measurement 
technique and use of a validated device. Difficulties 
may arise from the fact that only some devices avail-
able on the Polish market fulfil the quality criteria.
Specific indications for HBPM are listed in 
Table II.
2.2.2. Ambulatory blood pressure monitoring
Ambulatory blood pressure monitoring is usually 
undertaken for 24 hours (less frequently for 2 days). 
Measurement intervals are set at 15–30 minutes dur-
ing activity and 30–60 minutes during sleep. In-
creasing the number of BP measurements performed 
out-of-office, in conditions that reflect the usual pa-
tient environment, allows more reliable evaluation of 
actual BP values. Normal BP by ABPM is defined as 
mean daytime values below 135/85 mm Hg, mean 
night-time values below 120/70 mm Hg, and mean 
24-hour values below 130/80 mm Hg. Mean BP 
values obtained by ABPM (or HBPM) better reflect 
the risk of cardiovascular events and correlate more 
strongly with the presence of target organ damage 
compared to office BP values.
Despite clear clinical utility, ABPM also has some 
limitations including high cost, still suboptimal avail-
ability, and unclear reproducibility (though the latter 
is higher compared to office BP measurements). To 
obtain reliable measurements, it is necessary to use 
validated devices and a standardised measurement 
technique.
ABPM allows detection of prognostically adverse 
phenomena including white coat effect, excessive morn-
ing BP surge, and non-dipper, extreme-dipper, and 
reverse-dipper patterns of the circadian BP rhythm. 
A very important indication for ABPM is verification 
of the diagnosis of hypertension, particularly in patients 
with grade 1 hypertension by office BP measurements. 
Specific indications for ABPM are listed in Table V.
3. Investigations
At the time of the diagnosis of hypertension, all 
patients should undergo comprehensive clinical 
evaluation that includes targeted history, physical 
examination, and selected laboratory tests and other 
investigations as required.
The goals of clinical evaluation include identifica-
tion of:
1. The cause of elevated BP and indications for in-
vestigating for possible secondary hypertension.
2. Target organ damage and the presence and sever-
ity of other diseases, including cardiovascular and 
kidney disease.
3. Concomitant diabetes and its complications.
4. Other concomitant cardiovascular risk factors.
3.1. Patient history
Important issues to consider during history taking 
should include duration of hypertension, previous-
ly observed BP values, and previous treatment and 
its effects. Information should be obtained regard-
ing possible evidence of secondary hypertension, 
presence of risk factors and concomitant diseases, 
and the family history of hypertension, cardiovas-
cular disease, and kidney disease that might indi-
cate a hereditary background. Other medications 
taken by the patient that might affect BP values 
should be noted, along with possible evidence of 
noncompliance (the patient does not know names 
and doses of the medications, irregular visits, miss-
ing medical records, large variability of home BP 
values). In women, BP values during pregnancy 
should be ascertained. History should also be taken 
regarding substance use, including alcohol intake 
and tobacco smoking (quantified by the number 
of pack-years), changes in body weight, and dietary 
habits.
3.2. Physical examination
Complete physical examination should be performed 
in all patients, taking particular note of findings in-
dicating secondary hypertension and the presence of 
target organ damage.
Patient body weight and height should be docu-
mented, along with calculation of the body mass 
index (BMI), defined as body weight in kilograms 
divided by squared height in metres. Overweight 
is defined as BMI ≥ 25 kg/m2, and obesity as 
BMI  ≥  30  kg/m2. Due to the fact that interpreta-
tion of BMI values may be challenging in some pa-
tient groups (e.g., in the elderly), waist circumference 
should also be evaluated by measuring waist circum-
ference (in a horizontal plane at the superior aspect of 
the iliac crest) to identify abdominal obesity. In clini-
cal practice, waist circumference > 80 cm in women 
and > 94 cm in men should be considered alerting, 
and waist circumference > 88 cm in women and 
> 102 cm in men should be considered critical and 
clearly requiring weight reduction.
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3.3. Laboratory investigations
Laboratory investigations recommended in patients 
with hypertension may be categorised into:
1. Routine tests — necessary in all patients with 
hypertension.
2. Additional tests — performed in all patients if 
available.
3. Extended tests — performed in some patients 
during more extensive diagnostic work-up in ref-
erence centres.
3.3.1. Routine tests
Routine tests include:
• full blood count;
• fasting blood glucose level or oral glucose tolerance 
test (OGTT) if indicated;
• serum sodium and potassium level;
• total cholesterol, high-density lipoprotein (HDL) 
cholesterol, low-density lipoprotein (LDL) cho-
lesterol, and triglyceride levels;
• serum creatinine level with estimated glomerular 
filtration rate (eGFR);
• serum uric acid level;
• serum thyroid-stimulating hormone (TSH) 
level; 
• serum alanine aminotransferase (ALT) activity;
• urinalysis (with urine sediment examination);
• evaluation of albuminuria (by dipstick test or 
other method);
• 12-lead electrocardiogram (ECG).
Based on these routine tests, it is possible to ob-
tain information regarding the presence of HMOD, 
such as left ventricular hypertrophy (ECG), arterial 
stiffness (BP measurement, yielding pulse pressure 
Table V. Indications for and technique of ambulatory blood pressure measurements
Indications for ABPM
Confirmation of the diagnosis of hypertension in patients with grade 1 hypertension by office BP measurements and low/moderate cardiovascular 
risk
Suspicion of white-coat hypertension
— grade 1 hypertension by office BP measurements
— hypertension without target organ damage and with low global cardiovascular risk
— large BP differences in office measurements (> 20 mm Hg) or differences between home and office readings
Suspicion of masked hypertension
— high normal BP by office measurements
— normal office BP readings in individuals with subclinical target organ damage or high global cardiovascular risk
— suspicion of nocturnal hypertension and/or abnormal 24-hour BP pattern
Suspicion of hypotension (dizziness, falls, presyncope, syncope) or autonomic system dysfunction
Identification of true resistant or pseudo resistant hypertension
— suspicion of white-coat effect in treated hypertensives
Hypertension in pregnant women
Specific indications for ABPM
— hypertension in patients with glaucoma
— assessment of nocturnal BP values and fall in patients with obstructive sleep apnoea, diabetes, chronic kidney disease or after vascularized 
organ transplantation
Technique of ABPM
First, measure BP on both arms with a conventional sphygmomanometer according to the general principles (see Tab. I)
Depending on BP difference between arms:
≤ 10 mm Hg (SBP) — place the cuff on the non-dominant arm
> 10 mm Hg — place the cuff on the arm with higher BP reading
Choose an appropriately-sized cuff and measure BP using the automated device
If the difference between initial BP reading and BP read by the automated device is greater than 5 mm Hg, re-adjust the cuff
Set BP measurement intervals (preferred intervals 15–20 minutes during the day and 30 minutes during the night)
Switch off BP reading display
Provide the patient with a diary to record activity during the monitoring (along with a contact phone number)
A recording is acceptable if it includes at least 70% of the planned BP readings during the day and night
ABPM — ambulatory blood pressure monitoring; BP — blood pressure; SBP — systolic blood pressure
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as SBP minus DBP), and kidney damage (serum 
creatinine and eGFR, urinalysis with urine sediment 
examination).
3.3.2. Additional tests
For more complete evaluation of HMOD and 
cardiovascular risk and screening for secondary 
hypertension, additional tests to be performed 
in all patients with hypertension, if available, 
include:
• renal ultrasound with renal artery Doppler 
examination;
• echocardiography*;
• urinary albumin-to-creatinine ratio (UACR) 
(in morning urine sample);
• aldosterone-to-renin ratio (ARR) after 2 hours 
in upright position (patients with grade 2 and 3 
hypertension);
• fundoscopy (patients with grade 2 and 3 hyper-
tension).
In all women of childbearing age with hyperten-
sion, qualitative evaluation of proteinuria and renal 
ultrasound with renal artery Doppler examination 
should be performed. Quantitative evaluation of pro-
teinuria should be considered in all women planning 
pregnancy.
*Compared to ECG, echocardiography is more 
sensitive at detecting left ventricular hypertrophy 
and it provides important information regarding car-
diac structure and function. It allows more precise 
evaluation of the cardiovascular risk and is useful for 
monitoring treatment effectiveness during long-term 
follow-up. Echocardiographic examination should 
include evaluation of:
• left ventricular mass and interventricular septum 
and posterior wall thickness;
• left ventricular systolic function;
• left ventricular diastolic function (with particular 
consideration of left atrial size);
• presence of aortic dilatation and evidence of 
coarctation of the aorta;
• cardiac valves.
3.3.3 Extended tests
Depending on indications, investigations in patients 
with hypertension may be extended to include:
• carotid artery ultrasound;
• 24-hour ECG monitoring if arrhythmia is pre-
sent;
• ankle-brachial index (ABI);
• pulse wave velocity (PWV);
• 24-hour urinary sodium and potassium excre-
tion;
• quantitative evaluation of proteinuria/albumin-
uria.
Further specialised tests are used to identify some 
forms of target organ damage (e.g., magnetic reso-
nance imaging in subjects with suspected hyperten-
sive encephalopathy) and are usually necessary to 
confirm or exclude secondary hypertension. A sum-
Table VI. Routine, additional, and extended laboratory investigations in hypertensive patients
Routine tests
All patients with hypertension
Additional tests
All patients with hypertension 
if the test available
Extended tests
Depending on specific indications
Full blood count Renal ultrasound with renal artery Doppler examination Carotid artery ultrasound
Fasting plasma glucose level or OGTT 
if indicated
Urinary albumin-to-creatinine ratio 
(spot urine sample)
24-hour urinary sodium and potassium 
excretion
Serum total cholesterol, HDL cholesterol, 
LDL cholesterol, and triglyceride levels Echocardiography
24-hour ECG monitoring if arrhythmia 
is present
Serum sodium, potassium, and uric acid level Aldosterone-to-renin ratio after 2 hours in upright position Ankle-brachial index measurement
Serum creatinine level (with GFR estimation) Fundoscopy (patients with grade 2 and 3 hypertension) Pulse wave velocity measurement
Urinalysis (with urine sediment examination) Qualitative evaluation of proteinuria in women of childbearing age
Further search for cerebral, cardiac, 
renal and vascular damage
Serum ALT activity
Serum TSH level
12-lead ECG
ALT — alanine aminotransferase; ECG — electrocardiogram; GFR — glomerular filtration rate; HDL — high-density lipoprotein; LDL — low-density lipoprotein; OGTT — oral glucose tolerance test;  
TSH — thyroid-stimulating hormone
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mary of all investigations performed in patients with 
hypertension is shown in Table VI.
3.3.4. Assessment of the global cardiovascular risk
In most patients, concomitant factors affecting the 
global cardiovascular risk may be detected at the 
time of the diagnosis of hypertension. The global 
cardiovascular risk should be evaluated in all patients 
with hypertension based on BP values (hypertension 
grade) and the presence of other classical and non-
classical risk factors, subclinical target organ damage, 
cardiovascular disease, and chronic kidney disease 
(Tab. VII and VIII). The estimated risk is categorised 
as low, moderate, high, or very high. Interpretation 
of the level of risk (low, moderate, high, or very high) 
based on the Framingham model indicates that the 
Table VIII. Target organ damage, and metabolic, cardiovascular, and renal disease used for stratification of the global cardiovascular risk
Subclinical hypertension-mediated organ damage
Arterial stiffness: pulse pressure (in the elderly) ≥ 60 mm Hg
PWV >10 m/s
Electrocardiographic evidence of LVH
— Sokolov-Lyon index > 3.5 mV
— R in aVL > 1.1 mV
— Cornell voltage duration product >2440 mV × ms
Echocardiographic evidence LVH
LVM index: > 50 g/m2.7 in men, > 47 g/m2.7 in women (height in metres raised to the power of 2.7)
In subjects with normal body weight, LVM may be indexed for BSA: LVM/BSA > 115 g/m2 in men, > 95 g/m2 in women
Ankle-brachial index < 0.9
Chronic kidney disease — stage 3 with eGFR 30–59 mL/min/1.73 m2 (BSA) or stage ≥ 4 with eGFR < 30 mL/min/1.73 m2 (BSA)
Albuminuria 30–300 mg/24 h or urinary albumin–creatinine ratio 30–300 mg/g (3.4–34 mg/mmol) (preferably in morning spot urine)
Advanced retinopathy (haemorrhages or exudates, papilledema)
Diabetes
Uncomplicated diabetes (without organ damage)
Complicated diabetes (typical micro- and macroangiopathic complications)
Overt cardiovascular or renal disease
Cerebrovascular disease: ischemic stroke, cerebral haemorrhage, TIA
Cardiovascular disease: myocardial infarction, angina, myocardial revascularization
Presence of atherosclerotic plaques in imaging studies
Heart failure, including heart failure with preserved left ventricular ejection fraction
Symptomatic lower extremity peripheral arterial disease
Atrial fibrillation
BSA — body surface area; eGFR — estimated glomerular filtration rate; LVH — left ventricular hypertrophy; LVM — left ventricular mass; PWV — pulse wave velocity; TIA — transient ischemic attack
Table VII. Risk factors disease used for stratification of the global cardiovascular risk
Non-modifiable Modifiable
Male sex Smoking — current or past
Age (men ≥ 55 years, women ≥ 65 years) Hypercholesterolaemia
Premature menopause Hyperuricaemia
Family history of premature CVD (men < 55 years, women > 65 years)
Overweight and obesity
Sedentary lifestyle
Parental or family history of hypertension diagnosed at a young age
Psychosocial and socioeconomic factors
Resting heart rate > 80 beats per minute
CVD — cardiovascular disease
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10-year absolute cardiovascular event risk is below 
15%, 15–20%, 20–30%, and above 30%, respec-
tively. Using the European Systematic Coronary Risk 
Evaluation (SCORE) model, the 10-year absolute 
cardiovascular death risk for the above risk categories 
is below 1%, 1–5%, 5–10%, and above 10%, respec-
tively. Use of adjusted SCORE risk charts is recom-
mended in the European populations. In Poland, it 
is the Pol-SCORE 2015 risk chart (Tab. IX). Use of 
the SCORE risk chart is recommended in subjects 
above 40 years of age free from cardiovascular disease 
and diabetes. 
In all patients with hypertension, it is recom-
mended to estimate the global cardiovascular risk, 
taking into consideration the stage of hypertensive 
disease. Stage 1 is an uncomplicated disease which 
may be accompanied by non-modifiable and modi-
fiable risk factors for cardiovascular disease. Stage 2 
is an asymptomatic disease with HMOD, such as 
chronic kidney disease (stage 3) or uncomplicated 
diabetes. Stage 3 is an overt hypertensive disease 
with complications, such as cardiovascular disease, 
more advanced chronic kidney disease (stage > 3), 
or complicated diabetes (Tab. X). In patients with 
masked hypertension, the global risk is similar to 
that in subjects with overt (office) hypertension. In 
contrast, the risk is lower in those with white-coat 
hypertension.
Global cardiovascular risk level affects the choice 
of the treatment strategy and intensity of hyper-
tension treatment, and in particular the decisions 
regarding initiation of non-blood pressure-lowering 
therapy.
4. Therapeutic management
4.1. Overall goals and principles 
of the management
The basic goal of treatment in patients with hyper-
tension is to reduce mortality and the global risk 
of cardiovascular and renal complications. In par-
ticular, drug treatment should reduce BP to values 
considered target levels in hypertensives or, if it is 
not feasible, as close to these values as possible. This 
is based on numerous observations that effective 
BP lowering reduces the relative risk of death (by 
10–15%) and cardiovascular events (by 20%), par-
ticularly stroke (35%) and heart failure (40%), and 
delays progression of renal disease. These benefits are 
similar regardless of baseline severity of hypertension 
and cardiovascular risk, age, gender, and race. At the 
same time, global treatment strategy in the hyper-
tensive patient should include correcting all other 
modifiable cardiovascular risk factors, in particular 
body weight, serum cholesterol level, serum uric acid 
level, and heart rate.
4.1.1. Indications for antihypertensive therapy
Blood pressure measurement is the most important 
component of the clinical evaluation before mak-
ing a decision to initiate antihypertensive therapy. 
Clinical trials and metaanalyses indicate that the 
decision to initiate antihypertensive therapy should 
be based mostly on BP blood values and not evalu-
ation of the global cardiovascular risk, as relative 
benefits are the same regardless of the baseline risk. 
Although absolute risk reduction is higher in pa-
tients with high baseline cardiovascular risk, their 
residual risk with adequate BP control is also the 
highest, and thus delaying or preventing progres-
sion to the highest risk group is an additional ben-
efit of antihypertensive therapy in patients at lower 
baseline cardiovascular risk.
Non-drug treatment involving lifestyle changes 
is a necessary initial component of the management 
of hypertension and should be recommended at the 
first visit in all patients with suspected hypertension, 
including those with high normal BP. The decision to 
initiate drug treatment does not mean that lifestyle 
changes no longer need to be observed by the patient 
or pursued by the physician. At the same time, due to 
low patient compliance regarding lifestyle changes, 
institution of non-drug treatment should not delay 
the decision to initiate antihypertensive drug therapy, 
particularly in patients at higher cardiovascular risk.
If grade 3 (BP ≥ 180 and/or 110 mm Hg) or grade 
2 (BP ≥ 160 and/or 100 mm Hg) hypertension is 
found, as confirmed by at least two measurements 
at one or two occasions, respectively, drug treatment 
should be initiated immediately along with non-
pharmacological measures, prior to complete evalua-
tion of the risk profile.
If the observed BP values are consistent with 
grade 1 hypertension (140–159/90–99 mm Hg), 
non-pharmacological measures should be instituted, 
and the decision to initiate drug therapy should 
be made after comprehensive risk stratification. In 
patients at high or very high cardiovascular risk, 
drug treatment should be initiated immediately. In 
patients at low to moderate cardiovascular risk, non-
drug measures should be instituted for 3–6 months, 
followed by evaluation of the effects of non-drug 
treatment. If BP values remain at the grade 1 hy-
pertension range, an additional verification of the 
diagnosis of hypertension by ABPM is indicated. In 
patients with HMOD and/or overt cardiovascular 
disease, it is not necessary to verify the diagnosis 
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Notes
1. Persons with established cardiovascular risk or diabetes ar at high risk regardless of the presence of 
other risk factors (i.e., there is no need to assess the risk using the SCORE risk estimation chart).
2. Risk may be higher than indicated by the chart in persons:
— close to the next age category;
— with asymptomatic atherosclerosis (e.g., detected by vascular ultrasound examination);
— with strong family history of premature cardiovascular disease;
— with low HDL cholesterol level, elevated triglyceride level, impaired glucose tolerance;
—  obese and with a sedentary lifestyle.
Instructions on how to use the risk estimation chart
1. Find the appropriate table for given sex, smoking status and age, and then the cell nearest  
to the person’s systolic blood pressure and total cholesterol level. The value given in the cell  
shows the risk in percent.
2. By moving upwards, you can estimate the effect of the exposure to risk factors during  
the lifetime.
3. Risk value ≥ 5% should be considered high.
4. By using this card, it is possible to show to the patient how his/her risk changes if he/she, e.g., 
stops smoking or reduces other risk factors.
Table IX. Assessment of the global cardiovascular risk using the Pol-SCORE risk estimation chart
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of hypertension by ABPM, as initiation of antihy-
pertensive drug therapy is recommended both in 
grade 1 hypertension and in patients with white 
coat hypertension. In contrast, antihypertensive 
drug therapy is not recommended in patients with 
white coat hypertension if no HMOD is identified 
and/or cardiovascular risk is low to moderate. This 
recommendation is consistent with the 2018 ESC/
ESH guidelines and reflects changes introduced in 
the latter compared to the 2013 version.
An opinion has been upheld that routine antihy-
pertensive drug therapy is not necessary in patients 
with high normal BP (130–139/85–89 mm Hg). 
Only lifestyle changes are indicated in these sub-
jects, and the use of antihypertensive medications 
in those at high or very high cardiovascular risk is 
justified by other reasons (treatment of cardiovas-
cular disease, secondary prevention of cardiovas-
cular events, or an attempt to induce regression of 
HMOD).
Based on an analysis of clinical trials and the most 
recent metaanalyses, the principles of initiating anti-
hypertensive therapy in the elderly (> 65 years of age) 
are the same as in younger subjects. In particular, 
antihypertensive therapy in the elderly patients with 
grade 1 hypertension is considered necessary and not 
only reasonable. The HYVET study remains the only 
trial informing the management of the very elderly 
hypertensive patients (> 80 years of age). In this age 
group, antihypertensive therapy is recommended if 
SBP is ≥ 160 mm Hg.
The principles of initiating antihypertensive ther-
apy are summarised in Tables XI and XII.
4.1.2. Target blood pressure
Target BP is a threshold value below which pa-
tient’s BP should be kept during optimal antihyper-
tensive therapy. Only once these target BP values 
are reached, there is no need for further treatment 
intensification. In the past, recommendations re-
garding target BP values were often changed with 
publication of the results of large trials compar-
ing benefits of different target BP values during 
antihypertensive therapy. The currently prevail-
ing opinion, reflected in the 2017 American 
Heart Association/American College of Cardiology 
(AHA/ACC) guidelines and the 2018 ESC/ESH 
guidelines, is that the optimal reduction of the glob-
al cardiovascular risk in younger patients (< 65 years 
of age) is obtained by reducing BP below 130/80 
mm Hg in most patients with hypertension, includ-
ing those with concomitant ischaemic heart disease, 
previous myocardial infarction, or stroke. This major 
change in the approach to setting target BP reflects 
the results of the large randomised SPRINT trial, in 
which the target SBP of < 120 mm Hg was associ-
ated with a cardiovascular morbidity and mortality 
risk reduction by about 30% compared to the con-
ventional target SBP of < 140 mm Hg. As a result, 
some of the most recent metaanalyses that have 
included the SPRINT trial yielded similar conclu-
sions. However, there is a significant concern over 
the validity of the SPRINT trial conclusions due to 
the automated office BP measurement technology 
used in the study, resulting in lower BP values due 
to elimination of the white coat effect, and the trial 
protocol that involved recruiting mostly patients 
Table X. Evaluation of the global cardiovascular risk in hypertensive patients based on the Framingham model
Hypertension stage
Blood pressure [mm Hg]
High normal BP 
(130–139/85–89)
Grade 1 hypertension 
(140–159/90–99)
Grade 2 hypertension 
(160–179/100–109)
Grade 3 hypertension  
(≥ 180/110)
Stage 1  
No risk factors Low Low Moderate High
Stage 1  
1–2 risk factors Low Moderate Moderate/high High
Stage 1  
≥ 3 risk factors Low/moderate Moderate/high High High
Stage 2  
Target organ damage, 
diabetes without organ 
damage, CKD stage 3
Moderate/high High High Very high
Stage 3  
Overt cardiovascular 
disease, diabetes  
with organ damage,  
CKD stage ≥ 4
Very high Very high Very high Very high
BP — blood pressure; CKD — chronic kidney disease
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who already received combined antihypertensive 
treatment and were well adapted to low BP values. 
These concerns were shared by the authors of the 
2018 ESC/ESH guidelines who recommended SBP 
below 140 mm Hg — i.e., the previous BP tar-
get — as the initial therapeutic target regardless 
of the cardiovascular risk level and the presence 
of complications. If BP reduction to these values 
is well tolerated, the secondary therapeutic SBP 
target has been set at below 130 mm Hg, but 
not lower than 120 mm Hg, due to the J curve 
phenomenon observed in many clinical trials, i.e., 
relatively higher cardiovascular risk with too low 
achieved BP during antihypertensive therapy. It has 
also been noted that SBP values below 130 mm Hg 
should be achieved in most hypertensive patients. 
Table XII. Blood pressure (BP) thresholds for initiating antihypertensive therapy, target BP values, and undesirable levels of BP reduction 
in relation in relation to patient age and hypertension subtype
Systolic-diastolic 
hypertension at < 65 years 
of age
Systolic-diastolic 
hypertension at 65–80 
years of age
Systolic-diastolic 
hypertension at > 80 years 
of age
Isolated systolic 
hypertension
BP treatment 
threshold ≥ 140/90 ≥ 140/90 ≥ 160/90 ≥ 140
Initial therapeutic 
target SBP < 140 – – < 140*
Secondary thera-
peutic target SBP < 130 < 140 < 150 < 130*
Undesirable 
SBP reduction < 120 < 130 < 130 < 120*
Therapeutic 
target DBP < 80 < 80 < 80 –
Undesirable 
DBP reduction < 70 < 70 < 70 < 65
*In isolated systolic hypertension in the elderly and very elderly patients, thresholds for initiating antihypertensive therapy, target BP values, and undesirable levels of BP reduction apply for a given age. DBP — diastolic 
blood pressure; SBP — systolic blood pressure
Table XI. Initiation of antihypertensive therapy in relation to blood pressure values and the global cardiovascular risk
Clinical profile
Blood pressure [mm Hg]
High normal BP  
(130–139/85–89)
Grade 1 hypertension 
(140–159/90–99)
Grade 2 hypertension 
(160–179/100–109)
Grade 3 hypertension  
(≥ 180/110)
Non-drug therapy and antihypertensive drug therapy
Stage 1 
No risk factors No intervention
Lifestyle changes,  
confirmation by ABPM***  
if BP ≥ 140/90 
after 3–6 months,  
then add drugs
Lifestyle changes + drug 
treatment starting  
from the 2nd visit 
(i.e., at the diagnosis)**
Lifestyle changes + drug 
treatment starting  
from the 1st visit**
Stage 1 
1–2 risk factors Lifestyle changes
Stage 1 
≥ 3 risk factors Lifestyle changes
Stage 2 
Target organ damage, 
diabetes without organ 
damage, CKD stage 3
Lifestyle changes*
Lifestyle changes + drug 
treatment starting  
from the 1st visit**
Lifestyle changes + drug 
treatment starting  
from the 1st visit**
Stage 3 
Overt cardiovascular 
disease, diabetes  
with organ damage,  
CKD stage ≥ 4
Lifestyle changes  
+ consider drug  
treatment*
*In the high normal BP range, antihypertensive drugs are often indicated for reasons other than elevated BP (treatment of cardiac events, cardiovascular prevention, nephroprotection), without the need for reaching  
target BP < 130/80 mm Hg; **Reaching target BP values is indicated within 3 months; ***Or by home BP measurements; ABPM — ambulatory blood pressure monitoring; BP — blood pressure;  
CKD stage 3 — chronic kidney disease (eGFR 30–59 mL/min/1.73 m2); CKD stage ≥ 4 — chronic kidney disease (eGFR < 30 mL/min/1.73 m2); eGFR — estimated glomerular filtration rate
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At the same time, the target DBP level has been 
lowered to below 80 mm Hg, with on-treatment 
values in the 70–79 mm Hg range suggested for 
all hypertensive patients regardless of age and con-
comitant conditions. The 2018 ESC/ESH guide-
lines recommended these lower target BP levels also 
in patients with diabetes, previous stroke, or heart 
failure, although such patients were excluded from 
the SPRINT trial.
Despite the above concerns, these lower target BP 
levels were also adopted in the 2019 PTNT guide-
lines, as it can be argued that any divergent recom-
mendations on this major issue between the Polish 
and European guidelines would be confusing for the 
practising physicians.
There are two exceptions from the target BP levels 
given above. In the elderly patients (above 65 years 
of age), the recommended target BP values are be-
low 140/80 mm Hg (consistent with the 2018 ESC/
/ESH guidelines) but not less than 130/70 mm Hg.
In patients above 80 years of age, even more 
cautious SBP reduction to values below 150 mm 
Hg is recommended, based directly on the target 
SBP set in the HYVET trial which was the only suc-
cessful study in this age group.
In patients with ISH, it is recommended to 
reduce SBP below 140 mm Hg, and if these BP 
values are well tolerated in patients below 65 years 
of age, to values below 130 mm Hg but not less 
than 120 mm Hg. Due to low DBP values and an 
advanced age of most patients with this subtype of 
hypertension, attempts to reduce SBP to the target 
values should not lead to DBP reduction to values 
below 65 mm Hg.
It is recommended to reduce BP below 140/90 
mm Hg within 3 months, and then, if such a de-
cision is made, to achieve rapidly the ultimate 
therapeutic target, i.e., BP values below 130/80 
mm Hg. Rapid achievement of target BP values 
enhances patients’ trust in their physician (with im-
proved compliance) and increases cardiovascular risk 
reduction (VALUE study).
The criteria of antihypertensive therapy initiation, 
target BP values, and undesirable levels of BP re-
duction in relation to patient age and hypertension 
subtype are shown in Tables XI and XII.
4.1.3. Follow-up visits
Current practice indicates that in the initial treat-
ment phase, while the diagnosis of hypertension is 
confirmed and treatment is initiated and intensified, 
follow-up visits should be set at monthly intervals, 
and after adequate BP control is obtained, their fre-
quency may be reduced to once every 3 months. 
Intervals between follow-up visits should also depend 
on the degree of patient compliance, BP values, and 
the presence of target organ damage, concomitant 
disease, and other risk factors. The treatment regimen 
should be adjusted to patient lifestyle and needs, with 
simplification of the therapy, reduction of the daily 
number of tablets taken by the patient, involving 
family members in the therapeutic process, and tailor-
ing treatment to the financial situation of the patient.
4.1.4. Specialist consultation
A specialist consultation should be considered if:
• target BP has not been reached during 6 months 
of therapy despite treatment with an optimal 
combination of 3 drugs in full doses (including 
a diuretic);
• previously well controlled BP worsened despite 
continued use of drugs and without an obvious 
cause indicated by the history;
• clinical findings are present that may indicate 
secondary hypertension.
4.1.5. Discontinuation of antihypertensive  
drug therapy
Discontinuation of antihypertensive drug therapy 
may be considered in the following situations:
• in patients with grade 1 hypertension and low 
cardiovascular risk who are fully compliant with 
non-drug therapy, following a long period (≥ 12 
months) of good BP control as evidenced by both 
office and home measurements or ABPM;
• in young subjects in whom BP elevation was 
clearly associated with a stressful situation which 
is no longer present.
In these situations, drug doses or their number 
should be gradually and cautiously reduced but one 
should not withdrew all medications at once, and the 
patient requires frequent BP measurements.
4.2. Non-drug therapy
Non-drug therapy involves introduction of lifestyle 
changes that significantly reduce BP values in sub-
jects with hypertension, increase effectiveness of 
drug therapy, and may reduce the risk of cardiovas-
cular events and prevent development of hyperten-
sion in those with a family history of hypertension. 
However, due to poor patient compliance regard-
ing lifestyle changes, their formal recommendation 
should never delay initiation of drug therapy in 
patients with target organ damage or very high car-
diovascular risk.
Lifestyle changes that fulfil the above criteria 
include weight reduction, appropriate diet with 
reduced fat intake (particularly of saturated fats) 
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and increased vegetable and fruit intake, reduc-
tion of alcohol and salt intake, smoking cessation, 
and increasing regular physical activity.
4.2.1. Weight reduction and dietary 
recommendations
Excessive body weight (BMI > 25 kg/m2 — over-
weight, and BMI > 30 kg/m2 — obesity) is associated 
with an increased risk of hypertension, and weight 
reduction, and in particular reduction of abdominal 
obesity, not only results in BP lowering but also re-
duces dyslipidaemia and insulin resistance. A meta-
analysis showed that a 5 kg body weight reduction was 
associated with BP reduction by 4.4/3.6 mm Hg, and 
the BP-lowering effect of weight reduction was more 
pronounced in obese subjects compared to those 
with near-normal body weight. Weight reduction 
may also have a beneficial effect on the effectiveness 
of antihypertensive therapy.
Reduction of excess body weight (optimal 
BMI slightly below 25 kg/m2) should be obtained 
mostly by reduction of caloric intake and modi-
fication of diet composition (Tab. XIII). Patients 
are recommended to consume fruits and vegetables 
(300–400 g per day), fish (at least twice a week), 
low-fat dairy products, fibre, whole grain products 
and protein from plant sources, and to limit their 
saturated fat and cholesterol intake. These criteria are 
met by Mediterranean type diets.
Weight reduction efforts should also include reg-
ular exercise (Tab. XVII). In hypertensive patients, 
combining exercise with the Dietary Approaches to 
Stop Hypertension (DASH) study diet resulted in 
more pronounced body weight, BP and left ven-
tricular mass reduction compared to the DASH diet 
only.
If reduction of excessive body weight proves dif-
ficult or body weight is regained following weight 
loss, multidisciplinary therapeutic approach includ-
ing nutritional counselling is recommended.
Available data, mostly from observational studies, 
do not indicate a higher risk of incident hyperten-
sion or higher BP values in persons who regularly 
consume coffee. In contrast, consumption of energy 
drinks, licorice-containing products, and foods with 
high fructose content (i.e., with added glucose-fruc-
tose syrup) should be avoided.
4.2.2. Salt intake
A causal relationship has been proven between salt 
intake and BP values. Excessive salt intake may con-
tribute to resistance to antihypertensive treatment.
In patients with hypertension, reduction of salt in-
take by 4.4 g/day results in BP lowering by an average 
of 5.4/2.8 mm Hg. Hypertensive patients should 
not consume more than 5 g of salt per day (≤ 2 g 
of sodium) (Tab. XIV). BP-lowering effect of sodium 
intake reduction is seen in salt-sensitive subjects and is 
more pronounced in blacks, the elderly, and patients 
with diabetes, metabolic syndrome, and chronic kid-
ney disease. Limiting salt intake also allows a reduc-
tion of the number and doses of antihypertensive 
drugs. Evaluation of sodium intake should be based 
on 24-hour urinary sodium excretion measurements, 
although this approach may be prone to a significant 
error. Despite an inverse relationship between sodium 
excretion and total mortality found in the general pop-
ulation, no data are available to indicate that reducing 
large or moderate salt intake in hypertensives might 
be harmful. In addition, salt intake reduction in the 
Trial of Hypertension Prevention (TOHP) study was 
associated with a lower risk of cardiovascular events.
4.2.3. Alcohol consumption
A linear relation is observed between alcohol intake 
and BP values and cardiovascular risk. Increased al-
cohol consumption predisposes to more frequent 
occurrence of strokes and attenuates the effect of 
antihypertensive drugs.
The recommendation to reduce alcohol intake 
(Tab. XV) should also include avoidance of binge 
drinking and introduction of alcohol-free days dur-
ing the week.
Table XIII. Basic dietary recommendations for hypertensive pa-
tients, aiming for healthy body weight maintenance or reduction 
to normal values
Maintain daily caloric intake or reduce it in case of overweight 
or obesity
Increase intake of vegetables and other plant products (4–5 ser-
vings, 300–400 g/day) rich in potassium, e.g. tomatoes (300 g/day)*
Avoid products with high animal fat content (saturated fatty acids 
and cholesterol)
Substitute fish, fruits, vegetables, and other products containing 
unsaturated fatty acids for fatty animal products
*Excluding patients with renal failure or an increased risk of hyperkalaemia
Table XIV. Recommendations regarding salt intake 
in hypertensive patients
Reduce salt intake from usual 9–12 g to < 5 g per day (2 g Na)
To achieve this target:
• discontinue using salt when preparing meals at home and at the 
table
• consume meals prepared from fresh, natural products
• avoid products containing sodium compounds used as preser-
vatives
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4.2.4. Cigarette smoking
Smoking is one of the most important risk fac-
tors for cardiovascular disease and cancer. Smoking 
each cigarette induces a significant increase in BP 
and heart rate that persists for more than 15 min-
utes. Evidence is also available regarding harmful 
effects of passive smoking. In addition, smoking 
significantly increases the global risk of ischaemic 
heart disease, stroke and peripheral arterial disease, 
particularly in hypertensive patients in whom it 
attenuates the effect of antihypertensive drugs. Re-
ducing smoking habit is an important component 
of cardiovascular risk reduction efforts in hyper-
tensives (Tab. XVI). Smoking status of the patient 
should be ascertained at each visit. Smokers should 
be counselled to quit but the effectiveness of coun-
selling is limited. For this reason, medications to 
help quit smoking should be considered in those 
who have difficulty with quitting. It remains con-
troversial whether subjects unwilling to quit should 
be advised to use products that reduce exposure to 
the harmful components of tobacco smoke (tobacco 
heating systems instead of tobacco smoking), but 
these may be considered an intermediate step before 
quitting.
4.2.5. Physical activity
Regular physical activity may reduce BP by 2–11 mm 
Hg depending on its type. In patients with hyperten-
sion, the most pronounced BP-lowering effect has 
been observed for endurance training. Regular physi-
cal activity, even of moderate intensity, also helps 
reduce overweight, increase general fitness, and re-
duce mortality and cardiovascular risk. Patients with 
hypertension should be advised to engage in at least 
30 minutes of dynamic aerobic exercise of moderate 
intensity (e.g., jogging, brisk walking, cycling, swim-
ming) on 5–7 days per week, with gradual increase 
of the exercise duration to 300 minutes per week. 
Resistance exercises (building up muscle strength 
with a small dynamic component) may supplement 
physical activity 2–3 times per week. Basic recom-
mendations regarding increasing physical activity are 
summarised in Table XVII.
4.3. Antihypertensive medications
Large clinical trials have shown that effective BP con-
trol is the most important prerequisite for achieving 
the basic goal of treating hypertension, i.e., reduction 
of cardiovascular mortality and morbidity. In most 
hypertensive patients, drug treatment is necessary for 
that purpose along with lifestyle changes. The ESC/ 
/ESH guidelines, including the most recent 2018 
document, have indicated for years that based on 
multiple metaanalyses, the benefits of major anti-
hypertensive drug classes in terms of reducing mor-
tality and the overall risk of cardiovascular events 
are similar, reflecting their similar antihypertensive 
efficacy. For this reason, a limited attention has been 
paid in the ESC/ESH guidelines to the issue of an-
tihypertensive therapy individualisation, or specific 
indications for and contraindications to use of spe-
cific drug classes. In the opinion of the authors of 
the PTNT guidelines, an informed choice of specific 
drug classes may additionally optimise the treatment 
Table XV. Recommendations regarding alcohol intake in hyperten-
sive patients
Alcohol intake should be limited to:
• in men: 20–30 g of pure ethanol daily but not more than 140 g 
per week (e.g., 2 glasses of wine 5 times per week)
• in women: 10–20 g of pure ethanol daily but not more than 80 g 
per week (e.g., 1 glass of wine 5 times per week)
Note: 10 g of pure ethanol corresponds to 250 mL of beer, 100 mL 
of wine, and 25 g of vodka
Avoid binge drinking
Set alcohol-free days during the week
Table XVI. Recommendations regarding smoking in hypertensive 
patients
Each patient should be asked about smoking at each visit
Active counselling should be undertaken regarding smoking 
cessation
Minimum anti-nicotine intervention should be performed 
at least once a year
If necessary, recommend:
• nicotine replacement therapy
• treatment with bupropione
• treatment with cytisine
• treatment with varenicline
If these measures fail, refer patients to addiction treatment centres
Weight gain should be prevented
Table XVII. Basic recommendations regarding increased physical 
activity in hypertensive patients
Systematic exercise of moderate intensity for 30 minutes 
5–7 days a week 
Gradual increase in the duration of exercise up to at least 
300 minutes per week
Endurance exercises (walking, running, swimming) supplemented 
with resistance exercises (e.g., squatting), adjusted to age, conco-
mitant conditions, and patient preferences
Avoidance of strenuous isometric exercises (lifting heavy weights)
In patients with cardiac disease, exercise ECG testing and medically 
supervised rehabilitation may be necessary
ECG — electrocardiogram
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of hypertension if one takes into account the effect of 
the drug(s) on other cardiovascular risk factors, exist-
ing subclinical target organ damage, cardiovascular 
disease, and other concomitant disease; patient age 
and gender; possibility of drug interactions and ad-
verse effects; medication cost and financial situation 
of the patient; and previous physician experience 
with a given therapy (Tab. XXI). Thus, the position 
taken in the previous PTNT guidelines was upheld 
that the results of some large hypertension trials and 
their metaanalyses, along with pathophysiological 
clues and pharmacological differences, suggest a pos-
sibility of no class effect and/or better clinical utility 
of specific groups, subgroups, or individual drugs 
within drug classes, both major ones and others, in 
specific clinical situations, as indicated below when 
discussing specific drug classes and special patient 
populations, and in the table summary of antihyper-
tensive drug therapy individualisation (Tab. XXII). 
These differences between guidelines in the approach 
to the choice of antihypertensive drugs have also af-
fected the choice of single pill combinations recom-
mended in the PTNT 2019 guidelines.
4.3.1. Major drug classes
A review of the scientific literature indicates that 
despite numerous attempts, no new antihyperten-
sive drug classes that could both improve BP control 
and reduce cardiovascular risk have been introduced 
in the 21st century. The newest drug class — fol-
lowing renin inhibitors that have been introduced 
some years ago — is a combination of an angio-
tensin receptor blocker (ARB) and a neutral endo-
peptidase inhibitor (valsartan/sacubitril) but these 
drugs remain licensed only for use in heart failure. 
Although the benefits of antihypertensive drug thera-
py in reducing mortality and the risk of cardiovascu-
lar events are largely dependent on BP lowering per 
se, some antihypertensive drug classes are categorised 
as major, and other drug classes do not have this 
status. The criterion underlying this distinction is 
the presence or absence of data from large clinical 
trials showing significant benefits of a given class 
in reducing mortality and the risk of cardiovascular 
events in patients with hypertension. In the 2019 
PTNT guidelines — in accordance with the 2018 
ESC/ESH guidelines — it has been recommended 
that in uncomplicated hypertension, and in most 
cases of complicated hypertension and hypertension 
with concomitant diseases, except for hypertension 
in pregnancy, the first and second line choice for 
antihypertensive therapy should include medications 
from the five major drug classes with a proven ben-
eficial effect on reducing cardiovascular mortality 
and/or the risk of cardiovascular events. These are 
thiazide/thiazide-like diuretics, b-blockers, calcium 
antagonists, angiotensin-converting enzyme inhibi-
tors (ACEI), and ARB. In accordance with the above 
mentioned position regarding within-class differ-
ences between drugs, we continue to prefer certain 
subgroups within some major antihypertensive drug 
classes, with some modifications compared to the 
previous guideline edition (Tab. XVIII).
4.3.1.1. Thiazide/thiazide-like diuretics
Thiazide and thiazide-like diuretics are particularly 
useful in the elderly patients, subjects above 80 years 
of age (indapamide), those with ISH, and patients 
with a history of stroke. They are also often used as 
a part of combined antihypertensive treatment, par-
ticularly in patients with concomitant diabetes, those 
with renal dysfunction or with coexisting symptom-
atic heart failure. They are also a necessary compo-
nent of three-drug combinations in patients who 
require such therapy.
A position has been upheld from the 2015 PTNT 
guidelines that the preferred drugs in this class 
should be thiazide-like diuretics (chlorthalidone, in-
dapamide). Despite absence of head-to-head com-
parisons, which seem not to be feasible anymore, 
compared to conventional thiazide diuretics, more 
evidence of benefit regarding cardiovascular risk 
prevention in large-scale clinical trials (ALLHAT, 
ADVANCE, HYVET, PATS) has been obtained for 
thiazide-like diuretics in currently used lower doses 
that do not induce adverse metabolic effects, which 
has translated to an advantage of thiazide-like di-
uretics shown in some metaanalyses. In addition, 
thiazide-like diuretics exert a more potent and longer 
lasting BP-lowering effect, and their utility as mono-
therapy has been shown only for indapamide. An ad-
ditional argument in favour of thiazide-like diuretics 
comes from the recent reports indicating somewhat 
Table XVIII. Major classes of antihypertensive drugs
Five major classes of antihypertensive drugs
• with proven outcome benefits
• recommended for combined treatment and available as SPC
• used as monotherapy in specific situations
Thiazide diuretics (preferred thiazide-like agents)
b-blockers (preferred vasodilating and highly cardioselective 
agents)
Calcium antagonists (preferred dihydropyridines)
Angiotensin-converting enzyme inhibitors
Angiotensin receptor blockers
SPC — single pill combination
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increased risk of skin cancers (except for melanoma) 
associated with long-term hydrochlorothiazide use, 
although it is not known whether this association 
also holds for other thiazide diuretics. The two thia-
zide-like diuretics mentioned above provide a choice 
based on the expected diuretic effect, ranging from 
moderate (indapamide) to large (chlorthalidone). 
Attention should be paid to possible metabolic (dys-
lipidaemia and the risk of new-onset diabetes) and 
electrolyte disturbances (hypokalaemia, hyperuricae-
mia, hyponatraemia, and hypercalcaemia), and re-
spective laboratory parameters should be monitored 
during long-term therapy with conventional thiazide 
and thiazide-like diuretics due to the fact that an 
association was observed between long-term ben-
efits of these drugs and the occurrence of the above 
mentioned disturbances during treatment. All single 
pill combinations of two- and three drugs includ-
ing a thiazide-like diuretic that are available in Po-
land also include an ACEI (perindopril + indapami- 
de ± amlodipine), which is important when choos-
ing antihypertensive therapy in hypertensive patients 
with cardiac complications, and when the treatment 
needs to be intensified. It should also be noted that 
hydrochlorothiazide-containing single pill combina-
tions are available in Poland, e.g., in a combination 
with a vasodilating b-blocker (nebivolol + hydro-
chlorothiazide), which, in light of some recent data, 
might lead to their recommendation, for example, in 
hypertensive women with concomitant osteoporosis.
4.3.1.2. Beta-blockers
Indications for the use of b-blockers in the treatment 
of hypertension include tachycardia or an elevated 
heart rate above 80 beats per minute (bpm), ar-
rhythmia, evidence of a hyperkinetic circulation, par-
ticularly in younger subjects, and concomitant heart 
failure or coronary artery disease, particularly after 
a previous myocardial infarction, also in patients 
with concomitant chronic obstructive pulmonary 
disease (COPD).
In other clinical situations, b-blockers are not con-
sidered first-line drugs for the treatment of hyperten-
sion due to the fact that conventional cardioselective 
b-blockers (atenolol) were less effective in preventing 
cardiovascular events compared to the renin-angio-
tensin-aldosterone system (RAAS) inhibitors and 
calcium antagonists, particularly in regard to stroke 
prevention and inducing regression of left ventricular 
hypertrophy, which may be related to their weaker 
effect on central aortic pressure.
Due to introduction of elevated heart rate (> 80 
bpm) as a cardiovascular risk factor and availabil-
ity of bisoprolol in useful single pill combinations, 
the position from the previous PTNT guidelines 
has been modified and currently, two subgroups of 
beta1-adrenergic blockers are preferred — vasodilat-
ing agents and conventional highly cardioselective 
b-blockers.
The preferred b-blocker in younger patients with 
uncomplicated hypertension (< 40 years of age), old-
er hypertensive patients with concomitant ischaemic 
heart disease or heart failure, patients with hyperten-
sion and erectile dysfunction, and those with con-
comitant metabolic complications is a highly cardi-
oselective beta1-adrenergic blocker with vasodilating 
properties — nebivolol. It also seems justified to use 
this b-blocker for cardiovascular event prevention in 
patients with concomitant malignancy. This special 
position of nebivolol in the recent years has been 
reflected in the 2018 ESC/ESH guidelines which 
indicated a more favourable effect of nebivolol on 
central aortic pressure due to specific haemodynamic 
properties (smaller negative chronotropic effect and 
an additional vasodilating effect resulting from beta3-
adrenergic receptor activation). Of note, use of large 
nebivolol doses is now acceptable (up to 40 mg in 
the 2017 AHA/ACC 2017 guidelines), and 10 mg 
preparations have been introduced in Poland. The 
other vasodilating b-blocker, non-cardioselective 
carvedilol, is mostly useful in hypertension compli-
cated with heart failure.
Conventional, highly cardioselective beta1-adren-
ergic blockers, particularly bisoprolol, are preferen-
tially used in hypertensive patients with an elevated 
heart rate (> 80 bpm), concomitant ischaemic heart 
disease and/or heart failure, arrhythmia, and in case 
of combined antihypertensive therapy using single 
pill combinations. In these cases, due to the need to 
achieve desired heart rate reduction, conventional, 
highly cardioselective b-blockers, including bisopro-
lol, betaxolol, and long-acting metoprolol prepara-
tions, may be more useful than vasodilating beta1-
adrenergic blockers.
4.3.1.3. Calcium antagonists
Most large-scale clinical trials (ALLHAT, ASCOT, 
VALUE, ACCOMPLISH) that documented a ben-
eficial effect of calcium antagonists on the cardio-
vascular risk reduction used dihydropyridines and 
this subgroup is much more commonly used in 
the clinical practice. For these reasons, the position 
has been upheld from the 2015 PTNT guidelines 
that dihydropyridines should be preferred for an-
tihypertensive therapy. A negative inotropic effect 
of non-dihydropyridine calcium antagonists may be 
harmful in patients with heart failure or reduced left 
ventricular ejection fraction. In particular, the ef-
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ficacy and safety of long-acting dihydropyridines in 
the elderly, including patients with ISH (Syst-Eur), 
patients with peripheral arterial disease, and hyper-
tensive patients with concomitant COPD or asthma 
should be noted. An important advantage of calcium 
antagonists is their neutral metabolic effect, and thus 
these drugs are useful in combination with RAAS 
inhibitors in patients with concomitant lipid and/or 
carbohydrate metabolism disturbances. Some meta-
analyses suggest high efficacy of calcium antagonists 
in the prevention of atherosclerosis, and clinically in 
the prevention of stroke, but this was not confirmed 
in the studies on secondary stroke prevention. On 
the other hand, metaanalyses also indicate that these 
drugs are less effective in preventing heart failure and 
reducing proteinuria. Although most evidence for 
cardiovascular risk reduction in large-scale clinical 
trials was obtained for amlodipine, use of this drug 
is associated with a relatively high rate of leg oedema 
and thus lercanidipine and lacidipine are alternative 
long-acting but better tolerated drugs of this class. 
New reports highlight additional pleiotropic effects 
of new dihydropyridines, such as a nephroprotective 
effect of lercanidipine, which is not typical for other 
dihydropyridine calcium antagonist, or event their 
additional effect on the T-type calcium channels. 
At the same time, some studies reported potentially 
better prevention of dementia by older drugs of this 
class (amlodipine). Both amlodipine and lercani-
dipine are available in single pill combinations with 
RAAS inhibitors.
4.3.1.4. Angiotensin-converting enzyme inhibitors 
and angiotensin receptor blockers
An ACEI or ARB is a necessary component of first-
line antihypertensive therapy in the basic treatment 
algorithm. Both these classes of the renin-angioten-
sin system (RAS) inhibitors also have most indica-
tions in special patient populations.
Metaanalyses suggest additional benefits of ACEI 
in the prevention of cardiac events beyond their BP 
lowering effect that may be associated with bradyki-
nin-mediated effects of these drugs.
Differences between ACEI and ARB in regard 
to cardiovascular event prevention have not been 
commented in the 2018 ESC/ESH guidelines, al-
though since publication of the previous edition of 
these guidelines, three important metaanalyses were 
published, focusing on different patient populations, 
i.e., hypertensives, patients with hypertension and/or 
ischemic heart disease, and diabetic patients, which 
all showed an advantage of ACEI over ARB. The first 
of these metaanalyses suggested a special position of 
perindopril among ACEI, particularly in the context 
of combined treatment and use of single pill com-
binations as recommended in the 2018 ESC/ESH 
guidelines. Taking into account consistent results of 
these metaanalyses, the present 2019 PTNT guide-
lines upheld a modified position from the previous 
edition, indicating that ACEI should be preferred 
over ARB (with indications retained for telmisartan) 
in patients with hypertension and high cardiovas-
cular risk, particularly due to concomitant cardiac 
complications. This position has been reflected in 
the table that summarises individualisation of antihy-
pertensive drug therapy, as according to the cardiac 
societies’ guidelines, ACEI are preferred in patients 
with ischaemic heart disease and/or heart failure with 
elevated BP values. In contrast, ACEI and ARB are 
considered to have equivalent positions in hyperten-
sion without cardiac complications, which is also 
consistent with the European guidelines.
The above position was considered valid despite 
a metaanalysis published last year which suggested 
an equivalent cardiovascular risk reduction by ACEI 
and ARB with better tolerance of the latter. These 
results may be explained by the fact that this meta-
analysis only included head-to-head studies, while 
excluding placebo controlled trials and combined 
treatment studies, and thus, it was mostly based on 
the only large ONTARGET study which directly 
compared the effect of ramipril and telmisartan on 
cardiovascular mortality and morbidity in high car-
diovascular risk patients and showed no difference 
between these two drugs. 
Of note, in the SMILE-4 study, a sulfhydryl 
(-SH) group-containing ACEI zofenopril was more 
effective compared to ramipril, the comparator in 
the ONTARGET study, Further analyses from the 
SMILE studies also showed the efficacy of zofenopril 
in comparison with some other ACEI in patients 
with post-infarction left ventricular dysfunction, par-
ticularly those with hypertension.
Angiotensin-converting enzyme inhibitors also 
have a strong position in combination with a thia-
zide-like diuretic [as a single pill combination (SPC) 
of perindopril + indapamide], which stems from 
the results of clinical trials in patients with hyper-
tension and diabetes (ADVANCE) and in patients 
with a history of stroke (PROGRESS). In addition, 
only these RAS inhibitors (perindopril) are available 
in single pill combinations containing the preferred 
subgroup of thiazide-like diuretics.
Angiotensin receptor blockers are in turn preferred 
in patients with hypertension and target organ dam-
age, concomitant renal disease (including diabetic 
nephropathy), and in those with a history of stroke, 
with some metaanalyses suggesting that ARB prevent 
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stroke better than myocardial infarction. ARB are 
also the antihypertensive drug class which induces 
least common adverse effects and as a result, they are 
least commonly discontinued by the patients. For 
this reason, they are recommended in patients with 
cardiac complications as an alternative to ACEI if the 
latter are not tolerated.
4.3.2. Other antihypertensive drugs
Due to lack of prospective studies evaluating the 
effect on mortality and cardiovascular risk during 
antihypertensive therapy, other drug classes, such as 
a-blockers, aldosterone antagonists, loop diuretics, 
imidazoline receptor agonists, and peripheral and 
central sympatholytic drugs, are currently not recom-
mended as first- and second-line antihypertensive 
medications. However, this does not preclude use of 
these drugs during combination therapy if indicated 
individually, and in resistant hypertension, usually 
as third- to fifth-line drugs (Tab. XIX). Similarly 
to major antihypertensive drug classes, differences 
exist in regard to efficacy, safety, pharmacokinetic 
differences, and adverse effects also between spe-
cific drugs within other groups of antihypertensive 
medications in specific clinical situations. This is 
particularly the case for torasemide among loop di-
uretics (more favourable pharmacokinetics, potential 
additional pleiotropic effects), methyldopa among 
sympatholytic drugs (safety in the treatment of hy-
pertension in pregnancy), and spironolactone (higher 
efficacy) and eplerenone (less adverse effects) among 
aldosterone antagonists. It should be noted, however, 
that eplerenone is not licensed to treat uncompli-
cated hypertension in Poland. In patients with con-
comitant benign prostatic hyperplasia, uroselective 
tamsulosin should be rather used if hypertension 
requires one- or two-drug therapy, while resistant 
hypertension may sometimes require doxazosin use 
as this a-blocker exerts a BP-lowering effect.
4.4. Drug treatment algorithm
Previous antihypertensive drug algorithms recom-
mended in the European and American guidelines, 
and thus also in the PTNT guidelines allowed anti-
hypertensive drug therapy to be initiated using one 
(monotherapy) or two drugs (combined therapy us-
ing two medications or a single pill combination) 
chosen from major drug classes, followed by further 
modifications including medication substitution and 
increases in the number or dose of medications. The 
decision to initiate treatment with monotherapy or 
combined therapy depended on the severity of hy-
pertension and the degree of BP lowering necessary 
to reach target BP (PTNT guidelines) and/or car-
diovascular risk (ESC/ESH guidelines). In practice, 
as indicated by the epidemiological studies, such an 
approach allowed good BP control in about 25% of 
hypertensive patients in Poland, and in about 40% 
of patients who declared willingness to be treated. 
Thus, there was a need for a modified approach to 
antihypertensive drug therapy, as indicated in the 
2017 PTNT expert consensus document. In the 
2018 ESC/ESH guidelines, a completely new algo-
rithm for the management of hypertension has been 
adopted, recommending two-drug SPC as the initial 
treatment in a large majority of patients, followed by 
treatment intensification by using three-drug SPC 
if required. Initiating treatment with monotherapy 
has been reserved for rare, clearly defined situations. 
This management algorithm (Fig. 1) reflects ma-
jor changes in the antihypertensive drug treatment 
strategy: wide use of combined treatment using SPC 
as the initial treatment, despite lack of appropri-
ate licensing of most SPC preparations, and simpli-
fied treatment intensification with rapid transition 
to three drug therapy using SPC. It also indicated 
that such treatment strategy, with the addition of 
spironolactone if required, may allow adequate BP 
control in most patients. Practical management al-
gorithms based on this strategy, with some modifica-
tions regarding treatment intensification and wider 
indications for monotherapy in the elderly patients, 
taking into account differences between various age 
groups, are shown in Figures 2, 6 and 7 in the pres-
ent document.
4.4.1. Combined antihypertensive therapy 
using single pill combinations
Large-scale clinical trials indicate that in about 60% 
of hypertensive patients, good BP control may be 
achieved by using two antihypertensive medications 
with dose escalation if required, and in further 20% 
of patients, target BP values may be achieved by 
using three antihypertensive medications, provided 
that adequate compliance is achieved and maintained 
long-term. For these reasons, according to the new 
management algorithm, antihypertensive therapy 
Table XIX. Other drug classes useful as third- to fifth-line drugs 
in the treatment of hypertension and in special situations
Loop diuretics
Aldosterone antagonists
a-blockers
Central sympatholytic agents
Imidazoline receptor antagonists
Peripheral sympatholytic agents
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in most patients below 65 years of age is initiated 
(Step 1) with combined treatment using one of 
first-line SPC, i.e., combinations of an ACEI or 
ARB with a dihydropyridine calcium antagonist or 
a thiazide-like/thiazide diuretic in standard doses. 
If the initial therapeutic target is not reached, pos-
sible options (Step 2) include increasing drug dos-
es of the initially selected SPC, with escalation to 
maximal doses, or switching to a three-drug SPC 
in standard doses. Further treatment intensifica-
tion (Step 3) involves increasing drug doses of the 
selected three-drug SPC to maximal doses (Fig. 2). 
The rate of these treatment modifications and the 
approach to dose escalation depend on baseline 
BP values and the observed BP lowering, with 
the aim of achieving the initial therapeutic target 
(BP < 140/90 mm Hg) within 3 months. Further 
rapid treatment intensification is recommend-
ed over the next months if BP reduction below 
130/80 mm has not been achieved. If SBP falls be-
low 120 mm Hg, it is possible to reduce the dose of 
one of the SPC components.
Due to much increased importance of SPC in the 
2017 AHA/ACC guidelines, the 2018 ESC/ESH 
guidelines, and the present 2019 PTNT guidelines, 
the role of various groups and specific drugs largely 
depends on the availability of SPC containing these 
drugs.
Major two-drug combinations used for treat-
ment initiation in patients with uncomplicated hy-
pertension, and hypertensive patients with target 
organ damage, metabolic disturbances or a previous 
stroke include:
 — ACEI + dihydropyridine calcium antagonist;
 — ACEI + thiazide/thiazide-like diuretic;
 — ARB + thiazide diuretic;
 — ARB + calcium antagonist.
These combinations are well tolerated, effective in 
terms of BP lowering and cardiovascular risk reduc-
tion, and available in Poland as SPC with a large 
range of available doses.
Both thiazide/thiazide-like diuretic and dihydro-
pyridine calcium antagonist increase activity of the 
RAS, which potentiates the BP-lowering effect of 
Figure 1. Basic management algorithm for antihypertensive drug therapy in patients with uncomplicated hypertension, hypertension with 
target organ damage, after a stroke, and with concomitant diabetes or peripheral arterial disease according to the 2018 ESC/ESH guidelines. 
ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin receptor blocker; bpm — beats per minute; SPC — single pill combination
Two-drug SPC
ACEI or ARB + thiazide-like/thiazide diuretic 
or dihydropyridine calcium antagonist in a two-drug SPC
Hypertension
Add spironolactone or other drug
1 tablet (2 drugs)
1 tablet (3 drugs)
2 tablets (4 drugs)
Three-drug SPC
ACEI or ARB + thiazide-like/thiazide diuretic 
+ dihydropyridine calcium antagonist
Step 1.
Step 2.
Step 3. +
b-blocker as rst line drug in hypertensive patients:
   • with cardiac disease
Consider b-blocker as rst/second line drug in hypertensive 
patients:
   • with elevated heart rate > 80 bpm (young subjects)
   • women planning pregnancy
Consider monotherapy as rst step in hypertensive patients:
   •  grade 1 hypertension with low cardiovascular risk 
        (young subjects)
   •  grade 1 hypertension in the elderly (65–80 years of age)
   •  grade 2 hypertension in the very elderly (> 80 years of age)
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a RAS inhibitor. In addition, rates of typical adverse 
effects of diuretics (hypokalaemia, metabolic effects) 
and dihydropyridine calcium antagonists (peripheral 
oedema) decrease with concomitant use of a RAS 
inhibitor.
In a direct comparison, better cardiovascular risk 
reduction was shown for a combination of ACEI + cal-
cium antagonist compared to a combination of ACEI 
+ thiazide diuretic (ACCOMPLISH). No SPC con-
taining ARB + thiazide-like diuretic are available, and 
the only SPC containing ACEI + thiazide-like diuretic 
is a combination of perindopril and indapamide.
In turn, multiple available SPC of an ARB and 
a diuretic contain only hydrochlorothiazide. The BP-
lowering efficacy and clinical utility of these combi-
nations was shown in multiple trials (LIFE, VALUE).
Major three-drug combinations used in the new 
algorithm for the management of hypertension and 
available as three-drug SPC in Poland are:
 — ACEI + thiazide-like diuretic + calcium an-
tagonist;
 — ARB + thiazide diuretic + calcium antagonist.
Each of these combinations is currently available 
in Poland as only one SPC, i.e., perindopril + inda-
pamide + amlodipine and valsartan + hydrochloro-
thiazide + amlodipine. Studies showed improved BP 
control when using these combinations compared to 
two-drug combinations. Randomised trial analyses 
also indicate cardiovascular risk reduction with the 
former combination.
Two-drug combinations used in special patient 
populations or for multidrug therapy and available 
as SPC in Poland include:
 — dihydropyridine calcium antagonist + b-blocker;
 — thiazide-like diuretic + calcium antagonist;
 —  b-blocker + ACEI;
 — thiazide diuretic + vasodilating b-blocker.
A combination of b-blocker and dihydropyri-
dine calcium antagonist is used in young subjects, 
particularly women of reproductive age, in whom 
RAAS inhibitors should be avoided. A combination 
of calcium antagonist and thiazide-like diuretic is 
used in the elderly patients and those with ISH, and 
a combination of b-blocker and ACEI is recom-
Figure 2. Algorithm for antihypertensive drug therapy in patients with hypertension below 65 years of age. ACEI — angiotensin-converting 
enzyme inhibitor; ARB — angiotensin receptor blocker; BP — blood pressure; bpm — beats per minute; SPC — single pill combination
BP > target values
BP > target values
SPC
ACE-I or ARB + thiazide-like/thiazide diuretic 
or dihydropyridine calcium antagonist 
in standard doses
Two-drug SPC
in full doses
Three-drug SPC
in standard doses
Three-drug SPC
in full doses 
ACE-I or ARB Thiazide-like/thiazide diuretic Dihydropyridine calcium antagonist
1 tablet
1 tablet
1 tablet
1 tablet
1 tablet
1 tablet
b-blocker as rst line drug in hypertensive patients:
   • with cardiac disease
Consider b-blocker as rst/second line drug in hypertensive 
patients:
   • with elevated heart rate > 80 bpm (young subjects)
   • women planning pregnancy
Consider monotherapy as rst step in hypertensive patients:
   • grade 1 hypertension with low cardiovascular risk 
       (young subjects)
Hypertension
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mended for antihypertensive therapy in patients with 
hypertension and cardiac complications (ischaemic 
heart disease, heart failure). In the present guidelines, 
similarly to the 2018 ESC/ESH guidelines, a combi-
nation of vasodilating b-blocker and thiazide diuretic 
has been considered useful due to the results of many 
clinical trials that documented its benefits versus 
placebo in the early era of evidence-based medicine. 
However, this combination is mostly used in hyper-
tension with heart failure. It should be remembered 
that this combination offers less effective cardiovas-
cular event prevention (ASCOT and LIFE studies) 
and may be associated with a higher risk of metabolic 
disturbances and new-onset diabetes, although this 
risk is mitigated if a vasodilating b-blocker is used.
Finally, the armamentarium of combined antihy-
pertensive therapy also includes SPC in substandard 
doses (lower than those used for monotherapy), used 
for initiating treatment in patients who require great-
er caution, such as the elderly. Currently, such com-
binations of an ACEI (perindopril) with a thiazide-
like diuretic or a dihydropyridine calcium antagonist 
are available in Poland.
Note: RAAS inhibitors should be very cau-
tiously combined with potassium-sparing diuret-
ics as this combination may lead to hyperkalaemia. 
The two-drug combination of ACEI + ARB is not 
recommended due to an increased risk of adverse 
renal effects without additional benefits (ONTAR-
GET) or even with an increased risk (ALTITUDE). 
Non-dihydropyridine calcium antagonists (vera-
pamil and diltiazem) combined with b-blockers pre-
dispose to bradycardia and heart failure, and diuret-
ics combined with a-blockers predispose to ortho-
static hypotension. Possible two-drug combinations 
for the treatment of hypertension are summarised 
in Figure  3, taking into account their utility and 
availability of SPC, including so-called hybrid SPC 
(antihypertensive medication + statin).
Such a radical expansion of indications for com-
bined antihypertensive treatment and a strong posi-
tion of SPC stem from multiple benefits of such ther-
apy, summarised in Table XX. Some of the benefits of 
SPC (lower doses of individual drugs, which trans-
lates to better tolerance, and more rapid achievement 
of BP control) are in fact advantages of combined 
treatment. It should be noted that the metaanalysis 
by Wald et al. showed that the additional BP-low-
ering effect of combining drugs from two different 
classes in nearly 5-fold higher compared to doubling 
the dose of a single drug. This is also important in 
the context of VALUE study results which showed 
a significantly higher cardiovascular risk reduction in 
those patients in whom BP was controlled within the 
Figure 3. Two-drug combinations of antihypertensive drugs, taking into account their utility and availability of single pill combinations (SPC). 
ARB — angiotensin-receptor blocker; ACEI — angiotensin-converting enzyme inhibitor
Thiazide/thiazide-like 
diuretic
Proven cardiovascular 
risk reduction 
ARBb-blocker
Calcium antagonist
Statin
ACE-I
Other antihypertensive 
drugs
SPC available, rst line combinations
SPC available, combinations 
indicated for specic indications
No SPC, combinations acceptable
Combinations not recommended
Hybrid combinations with a statin
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initial 6 months of treatment. Further benefits are 
directly related to the SPC form, i.e., lower number 
of tablets and convenient dosing, and translate to the 
most important advantage of SPC, i.e., improved 
patient adherence to treatment, including both com-
pliance and persistence, which leads to a further 
increase in the antihypertensive treatment efficacy 
(STITCH and ACCOMPLISH studies).
At the same time, previously postulated lower flex-
ibility of SPC dosing used to be related to the fact 
that many such preparations were available in only 
one combination of doses, as also reflected by the for-
mer term “fixed dose combination” (FDC), implying 
precisely defined, fixed proportions of the compo-
nents of a combined preparation. This is, however, 
no longer true with the current availability of dif-
ferent dose combinations of a given SPC. Currently, 
most SPC have from 3 (two-drug SPC) to 6 (three-
drug SPC) dose combinations available, which allows 
flexible treatment modification, particularly with the 
present recommendation of dose escalation every 
2–4 weeks if BP remains inadequately controlled in 
the initial treatment phase to reach target BP. 
4.4.2. Indications for monotherapy
Indications for initiating therapy with a single drug 
have been much restricted as in monotherapy, most 
current antihypertensive agents lower BP by less 
than 20/10 mm Hg and such a BP-lowering effect 
is seen in only about 50–60% of patients. For these 
reasons, monotherapy may only be considered 
in specific situations. The first of these is grade 1 
hypertension in subjects at low cardiovascular 
risk. In practice, these are young subjects with SBP 
of 140–150 mm Hg, often with elevated heart rate, 
who require either a vasodilating b-blocker (more 
beneficial effect on central aortic pressure) or, if 
normalisation of heart rate proves difficult, a con-
ventional cardioselective b-blocker (stronger nega-
tive chronotropic effect). Another such situation is 
grade 1 hypertension in the elderly subjects, or 
grade 2 hypertension in subjects above 80 years 
of age, due to higher target BP values and potential 
consequences of hypotension. In those patients, 
dihydropyridine calcium antagonists or thiazide-
like diuretics may be considered, with preference 
of indapamide in those above 80 years of age. The 
pathophysiological basis for such initial drug choice 
is the fact that RAAS inhibitors and b-blockers are 
more frequently effective in younger patients, often 
with so called resistance, high-renin, or hyperki-
netic hypertension, while thiazide-like diuretics and 
calcium antagonists are more effective in older pa-
tients who are more frequently characterised by vol-
ume or low-renin hypertension. Patient gender may 
also be factor, as RAAS inhibitors should be avoided 
in women of reproductive age, and b-blockers or 
calcium antagonists should be preferred instead.
It should be remembered that treatment benefits 
are mostly related to BP lowering, and thus medica-
tions characterised by a high trough-to-peak (T/P) 
ratio are preferred, particularly in monotherapy, as 
they provide better 24-hour BP control and may be 
given once daily.
Increasing the drug dose to the maximum dose 
exerts little additional BP lowering effect but largely 
increases the risk of adverse effects. Thus, if mono-
therapy using a standard drug dose is not effective 
enough, adding a second drug by switching to an 
appropriate SPC has been considered the optimal 
next step among possible options.
4.4.3. Masked hypertension and chronotherapy 
of hypertension
Studies based on ABPM indicate that in many pa-
tients, additional cardiovascular risk is associated 
with masked hypertension. This mostly involves el-
evated BP values during the night and may be as-
sociated with a non-dipping BP pattern. The 2018 
ESC/ESH guidelines were the first to indicate that 
antihypertensive therapy should be used in patients 
with masked hypertension, while the PTNT guide-
lines have recommended chronotherapy in this pa-
tient group for many years. Typical morning dosing 
of long-acting antihypertensive drugs may not allow 
adequate BP control during the night and may not 
correct these disturbances of the circadian BP profile. 
In these circumstances, i.e., with the non-dipping BP 
pattern and masked nocturnal hypertension, modifi-
cation of the timing of antihypertensive drug admin-
istration with evening drug dosing should be con-
sidered (Fig. 4). As this approach to chronotherapy 
of hypertension, first suggested in the 2011 PTNT 
Table XX. Advantages of combined antihypertensive drug therapy 
and single pill combinations
More potent BP reduction
More rapid and more frequent attainment of BP control
Lower doses of individual drugs
Better tolerance (fewer adverse effects)
Fewer tablets
More convenient therapy
Lower costs
Improved compliance
Reduced therapeutic inertia
BP — blood pressure
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guidelines, has become popular, it should be stressed 
that such evening dosing of antihypertensive drugs 
must be based on an evaluation by ABPM (non-
dipping pattern) and should mostly involve dosing 
of RAS inhibitors. Evening dosing of ARB or ACEI 
(with a general preference of shorter-acting drugs and 
those tested in chronotherapy studies, e.g., ramipril 
and valsartan) was associated with an improved cir-
cadian BP pattern and reduced microalbuminuria. It 
also proved safe in large-scale clinical trials (HOPE, 
Syst-Eur). Evening dosing of antihypertensive drugs 
is contraindicated in patients with glaucoma. In view 
of a strong tendency to prefer SPC, it should be 
stressed that the above mentioned RAS inhibitors 
are components of various SPC, and combinations 
with a dihydropyridine calcium antagonist may be 
administered at the evening, as amlodipine provides 
a uniform BP-lowering effect over 24 hours regard-
less of the timing of its administration.
5. Special patient populations
5.1. Individualisation of antihypertensive 
therapy
The approach to drug therapy adopted in the current 
and previous guidelines gives much emphasis to its 
individualisation (Tab. XXI).
The choice of first-line therapy is important due to 
potential benefits beyond BP lowering documented 
in large-scale clinical trials in specific clinical situa-
tions. At the same time, current recommendations 
regarding individualisation of antihypertensive ther-
apy must be consistent with the new management 
algorithm and include use of different SPC. With 
so many different available SPC, this is possible for 
the most common cardiovascular and renal compli-
cations and metabolic disturbances accompanying 
hypertension (Fig. 5). Individualisation of antihyper-
tensive therapy may also offer additional benefits, or 
allow avoiding adverse effects in specific conditions 
due to different pharmacological properties of an-
tihypertensive medications. Specific indications for 
and contraindications to different drug classes are 
shown in Tables XXII and XXIII.
5.2. Hypertension in the elderly
Large clinical trials and metaanalyses indicate that 
antihypertensive therapy in patients above 65 years of 
age significantly reduces the stroke rate, heart failure 
incidence, and cardiovascular mortality. Although 
patients with baseline SBP ≥ 160 mm Hg were re-
cruited to the available clinical trials specifically tar-
geting this age group, and SBP was lowered in these 
Table XXI. Individualization of drug therapy
When choosing (or avoiding) any particular drug combination  
(or drug), the following should be taken into consideration:
• availability of single pill combinations (SPC)
• possibility of initiating and intensifying therapy using SPC
• presence of cardiovascular and renal disease
• presence of other concomitant conditions
• presence of other cardiovascular risk factors and target organ 
damage
• demographic factors (age, gender, race, body weight)
• 24-hour blood pressure-lowering efficacy of a drug
• drug adverse effect profile
• drug cost — but never at the price of lower treatment effective-
ness and tolerance
• previous physician and patient experience with a given drug 
(drugs)
Figure 4. Suggested timing of antihypertensive drug administration in relation to the 24-hour blood pressure (BP) profile
Antihypertensive drug in the morning
Dipper
Non-dippers
Preserved normal BP prole (dipping pattern)
Restoration of normal BP prole (dipping pattern)
Antihypertensive drug in the evening
Reduction of morning BP surge
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studies below 150 mm Hg but not below 140 mm 
Hg, the elderly subjects also comprised a majority 
in multiple clinical trials that confirmed benefits of 
antihypertensive therapy with BP lowering below 
140/90 mm Hg, regardless of baseline severity of 
hypertension. Despite the fact that the elderly pa-
tients comprised a large group of the SPRINT trial 
participants, concerns over this study led to a recom-
mendation of target BP below 140/80 mm Hg, if 
the patient is in a good overall condition and toler-
ates the therapy well, in both the 2018 ESC/ESG 
guidelines and now the 2019 PTNT guidelines. It is 
not recommended to lower SBP below 130 mm Hg.
Benefits of antihypertensive therapy in the elderly 
are similar to those obtained in younger age groups. 
However, due to a reduced adaptive capacity of the 
cardiovascular system and the risk of orthostatic hy-
potension, therapy should be more cautious, and 
target BP values should be reached more gradually. 
Due to the risk of orthostatic hypotension and falls, 
BP in the elderly hypertensive should be measured 
after 1 and 3 minutes of standing (orthostatic test-
ing) in the following situations:
• therapy initiation;
• treatment change;
• history of falls;
• dizziness or near-fainting;
• concomitant diabetes.
It should also be noted that the HYVET study re-
mains the only dedicated study (and not a subanaly-
sis) that showed benefits of antihypertensive therapy 
in patients above 80 years of age. For this reason, 
a recommendation has been upheld that in this pa-
tient group, antihypertensive therapy should be initi-
ated if SBP is 160 mm Hg or above, aiming for target 
SBP below 150 mm Hg (Tab. II). However, due to 
differences in the general health condition of these 
individuals, the decision to initiate therapy should 
be individualised, and BP lowering should be gradual 
and carefully monitored by the physician. A decision 
to initiate antihypertensive therapy in patients with 
frailty syndrome, which is common among those 
above 80 years of age, 
The basic principles of non-drug therapy in the 
elderly hypertensives are the same as in younger sub-
jects but limitations due to impaired mobility and 
reduced fitness, precluding regular exercise, should 
be borne in mind.
All major classes of antihypertensive medications 
were tested in large-scale clinical trials in the elderly 
patients, and recent metaanalyses do not indicate 
any differences in the efficacy of antihypertensive 
Figure 5. Preferred choices of single pill combinations/combined therapy and intensification of antihypertensive drug therapy in relation 
to concomitant conditions. ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin-receptor blocker; BP — blood pressure
Previous myocardial infarction
Heart failure
b-blocker + ACE-I
Target BP not reached within 2–4 weeks
b-blocker + ACEI+ calcium antagonist 
or thiazide-like/thiazide diuretic 
b-blocker + ACE-I + calcium antagonist
or thiazide-like/thiazide diuretic 
+ aldosterone antagonist
Previous stroke
Diabetes
Renal dysfunction
Elderly
ACE-I/ARB + thiazide-like/thiazide diuretic ACE-I/ARB + calcium antagonist
ACE-I/ARB + thiazide-like/thiazide diuretic
+ calcium antagonist
Metabolic syndrome
Diabetes
ACE-I/ARB + thiazide-like/thiazide diuretic 
+ calcium antagonist + aldosterone antagonist
Target BP not reached within 2–4 weeks
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Table XXII. Preferred first (I) and second (II) choice antihypertensive drug classes* in specific conditions
Clinical condition
Preferred first and second choice drugs
I — first choice drug
II — second choice drug for combined 
treatment
A — with angina
B — with b-blocker intolerance
C — with angiotensin-converting enzyme 
inhibitor intolerance
D — after myocardial infarction
1 — preferred agents: perindopril, ramipril, 
zofenopril
2 — preferred agents: telmisartan and 
valsartan
3 — only carvedilol, bisoprolol, metoprolol 
XR/CR, nebivolol
4 — preferred agents: candesartan and 
valsartan
5 — preferred agent: indapamide
6 — preferred agents: perindopril, ramipril
7 — telmisartan has the first-choice status
8 — only indapamide
9 — preferred agent: lercanidipine
10 — preferred agent: labetalol (poor ava-
ilability in Poland), of other b-blockers only 
metoprolol
11 — only nifedipine (extended release 
preparation preferred)
12 — only verapamil
13 — only nebivolol
TD — thiazide/thiazide-like diuretics
BB — b-blockers
CA-dhp — dihydropyridine calcium anta-
gonists
CA-ndhp — non-dihydropyridine calcium 
antagonists
ACEI — angiotensin-converting enzyme 
inhibitors
ARB — angiotensin receptor blockers
AA — aldosterone antagonists
LD — loop diuretics
MD — methyldopa
TD BB CA-dhp
CA-
ndhp ACEI ARB AA LD MD
Left ventricular 
hypertrophy         I I
Ischemic heart disease   I II A II B I 1 II C 2 II D
Heart failure II I 3     I II C 4 II II
Permanent 
atrial fibrillation   I   I
Tachyarrhythmias   I
Aortic aneurysm I
Peripheral arterial 
disease I I
Previous stroke I 5       II I
Metabolic syndrome     II II I I
Diabetes II 5 II   I 6 I
Patients with multiple 
cardiovascular 
and metabolic 
complications
I 6 II C 7
Hyperuricaemia/gout          I I 
Hypertension 
in the elderly I   I   II II
Hypertension 
above 80 years of age I 8       II
Isolated systolic 
hypertension I   I   II II
Albuminuria/
/proteinuria     II 9 II I I
Diabetic/non-diabetic 
nephropathy         I I
Chronic kidney disease         I I   II
Pregnancy   II 10 II 11 II 12         I
Erectile dysfunction   II 13 II    I I
Asthma/chronic 
obstructive pulmonary 
disease
    I     I
Glaucoma   I
*SPC should contain two first-choice drugs or one first-choice drug and one second-choice drug, except for not recommended combinations of ACEI + ARB and BB + CA-ndhp (SPC not available)
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medications in relation to the patient’s age. However, 
as dictated by the clinical experience, and if there 
are no specific indications to individualise therapy 
otherwise, first-line drugs are thiazide/thiazide-like 
diuretics and dihydropyridine calcium antagonists, 
which may be used in monotherapy in grade 1 hy-
pertension. The preferred SPC in uncomplicated 
hypertension in this age group is a combination of 
thiazide-type diuretic and dihydropyridine calcium 
antagonist, while patients with cardiovascular dis-
ease should receive an ACEI-containing SPC, and 
those after a coronary event should receive ACEI + 
b-blocker. The principles of antihypertensive therapy 
in the elderly patients are shown in Table XXIV, 
and the modified algorithm for the management of 
hypertension in patients aged 65-80 years is shown 
in Figure 6.
In patients above 80 years of age, available studies 
(HYVET) indicate that the therapy should be initi-
ated with a long-acting thiazide-like diuretic (inda-
pamid), with a possible addition of an ACEI, and in 
those with grade 3 hypertension, a respective SPC 
should be used. The modified algorithm for the man-
agement of hypertension in patients above 80 years 
of age is shown in Figure 7.
5.3. Isolated systolic hypertension 
in the elderly
Isolated systolic hypertension is defined as persis-
tently elevated SBP (> 140 mm Hg) with normal 
DBP values (< 90 mm Hg). It a predominant form 
of hypertension in the elderly patients. The patho-
genesis of this type of hypertension has been well 
defined and is related to reduced large elasticity and 
compliance of the aorta and other large arteries due 
to age- and atherosclerosis-related calcium and col-
lagen deposition, replacing elastin in the large artery 
walls. Due to these changes, the capacitance function 
of the aorta is reduced, leading to an increase in SBP 
and a decrease in DBP.
Tabela XXIII. Absolute and relative contraindications to specific antihypertensive drug classes
Drug class Absolute contraindications Relative contraindications
Thiazide diuretics Gout
Metabolic syndrome
Glucose intolerance
Hyponatremia < 130 mmol/L
Pregnancy
b-blockers Asthma 2nd or 3rd degree atrioventricular block
Chronic obstructive pulmonary disease
Metabolic syndrome
Glucose intolerance
Athletes and physically active patients
Dihydropyridine calcium antagonists
Tachyarrhythmias
Heart failure
Non-dihydropyridine calcium antagonists 
(verapamil/diltiazem)
2nd or 3rd degree atrioventricular block
Chronic constipation (verapamil)Heart failure
Bradycardia < 50 bpm
Angiotensin-converting enzyme inhibitors
Pregnancy
Hyperkalaemia > 5.0 mmol/L
Bilateral or single kidney renal artery stenosis
Transplant renal artery stenosis
History of angioneurotic oedema
Angiotensin receptor blockers
Pregnancy
Hyperkalaemia > 5.0 mmol/L
Bilateral or single kidney renal artery stenosis
Aldosterone antagonists
Chronic kidney disease (eGFR < 30 mL/min)
Hyperkalaemia > 5.0 mmol/L
Pregnancy
bpm — beats per minute; eGFR — estimated glomerular filtration rate
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While SBP is the major determinant of cardio-
vascular risk, reduced DBP is a pathophysiological 
determinant of the so-called J-curve, or an increase 
in ischaemic heart disease risk with excessive DBP 
lowering. This has therapeutic implications, as efforts 
to reduce SBP are associated with a risk of exces-
sive DBP lowering, and it has been reflected in the 
recommendations on target BP values in this type of 
Table XXIV. Antihypertensive treatment strategies in the elderly
In patients aged 65–80 years, regardless of hypertension grade, initiation of antihypertensive therapy according to the general principles is recom-
mended
In patients aged 65–80 years, target BP < 140/90 mm Hg is recommended if the treatment is well tolerated but BP should not be lowered below 
130/70 mm Hg
In patients > 80 years of age with grade 2–3 hypertension, drug therapy to reduce SBP to 140–150 mm Hg is recommended, provided the patient 
is in a good physical and mental condition
In patients who reach 65 or 80 years of age, continuation of previous well-tolerated antihypertensive therapy should be considered regardless of 
achieved/target BP values
In patients > 80 years of age with grade 1 hypertension, drug therapy is not recommended
In the elderly, initial drug doses should be lower, and subsequent therapy intensification should be more cautious due to a higher risk of adverse  
effects (hypotension). Monotherapy is acceptable in patients aged 65-80 years with grade 1 hypertension and patients > 80 years of age  
with grade 2 hypertension
All major drug classes may be used for monotherapy, with some preference for dihydropyridine calcium antagonists and thiazide-like diuretics.  
SPC may contain drugs from these two classes or one of these drugs and ACEI or ARB
In the elderly with isolated systolic hypertension, the preferred drugs are thiazide/thiazide-like diuretics, dihydropyridine calcium antagonists,  
and SPC containing one of these drugs and ACEI or ARB 
In patients > 80 years of age, the preferred first line drug is indapamide, combined with ACEI in SPC
ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin receptor blocker; BP — blood pressure; SBP — systolic blood pressure; SPC — single pill combination
ACE-I or ARB Thiazide-like/thiazide diuretic Dihydropyridine calcium antagonist
1 tablet
1 tablet
1 tablet
1 tablet
1 tablet
1 tablet
BP > target values
BP > target values
Two-drug SPC 
in full doses
Three-drug SPC
in full doses
Grade 1 hypertension Grade 2–3 hypertension
Two-drug SPC 
in standard doses
Three-drug SPC
in standard doses
Monotherapy (thiazide-like diuretic 
or dihydropyridine calcium antagonist) 
or SPC (ACE-I/ARB + thiazide-like/thiazide 
diuretic or dihydropyridine 
calcium antagonist) 
in substandard doses
SPC (thiazide-like diuretic 
+ dihydropyridine calcium 
antagonist or ACE-I/ARB 
+ thiazide-like/thiazide diuretic 
or dihydropyridine calcium antagonist) 
in standard doses 
Figure 6. Algorithm for antihypertensive drug therapy in patients with hypertension aged 65-80 years. ACEI — angiotensin-converting enzy-
me inhibitor; ARB — angiotensin receptor blocker; BP — blood pressure; SPC — single pill combination
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hypertension (SBP should be lowered according to 
the general recommendations for specific age groups 
but DBP should not be lowered below 65 mm Hg). 
It should be remembered that antihypertensive agents 
induce proportional lowering of both SBP and DBP 
and despite some differences between them, they can-
not rapidly affect aortic compliance which determines 
SBP elevation with concomitant DBP reduction.
In patients with ISH, thiazide/thiazide-like di-
uretics and dihydropyridine calcium antagonists are 
preferred, possibly with an addition of a RAS inhibi-
tor. This recommendation stems from the three clini-
cal trials in patients with this type of hypertension 
(SHEP, Syst-Eur, HYVET).
5.4. Hypertension in women
In the Blood Pressure Lowering Treatment Trialists’ 
Collaboration metaanalysis that compared benefits 
of antihypertensive therapy in men and women, both 
similar BP-lowering effect and similar treatment out-
comes were noted in both genders, with no differenc-
es in response to different classes of antihypertensive 
medications. 
Hypertension management in women of repro-
ductive age, during pregnancy, and in the postpar-
tum period has been discussed in a separate expert 
consensus statement of the Polish Society of Hyper-
tension (PTNT), the Polish Cardiac Society (PTK), 
and the Polish Society of Gynecologists and Obste-
tricians (PTGP). The basic management principles 
are summarised in Tables XXV and XXVI.
Among the 5 major antihypertensive drug classes, 
calcium antagonists (preferably dihydropyridines) 
and/or b-blockers should be considered in women 
of reproductive age. Thiazide/thiazide-like diuretics 
may also be considered but these should be with-
drawn during pregnancy. In hypertensive women 
planning pregnancy, a choice of a b-blocker which 
may be later continued during pregnancy if required 
should be considered (e.g., metoprolol). Basic two-
drug combinations which may be used in women of 
reproductive age include dihydropyridine calcium 
antagonist + b-blocker and calcium antagonist + thia-
zide/thiazide-like diuretic (SPC are available that 
contain these combinations).
In women of reproductive age, substituting drugs 
typically used during pregnancy for regular chronic 
antihypertensive therapy may be considered already 
when planning pregnancy (particularly labetalol and 
extended-release nifedipine, if these drugs were avail-
able in Poland in the future). Use of drugs recom-
mended during pregnancy may also be considered 
in women in whom use of assisted reproduction 
technology is planned.
ACE-I Thiazide-like/thiazide diuretic Dihydropyridine calcium antagonist
Grade 2 hypertension Grade 3 hypertension 
BP > target values
BP > target values
Three-drug SPC
in full doses
Two-drug SPC 
(indapamide-based)
in full doses
Two-drug SPC (indapamide-based) 
in standard doses
Monotherapy 
(indapamide)
Two-drug SPC 
(indapamide-based)
in standard doses
Three-drug SPC
in standard doses
Figure 7. Algorithm for antihypertensive drug therapy in patients with hypertension aged > 80 years. ACEI — angiotensin-converting enzyme 
inhibitor; ARB — angiotensin receptor blocker; BP — blood pressure; SPC — single pill combination
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In women of reproductive age, ACEI, ARB, renin 
inhibitors, and mineralocorticoid receptor antago-
nists should not be used due to potential teratogenic 
effects of these drugs.
Hypertension is not an absolute contraindication 
for the use of hormonal replacement therapy or oral 
contraception. If these therapies are used, BP should 
be measured at each visit and hypertension should be 
treated according to the general management principles.
The likelihood of BP increase in hypertensive 
women who receive hormone replacement therapy 
during menopause is small, but hormone replace-
ment therapy and selective oestrogen receptor modu-
lators should not be used for primary or secondary 
prevention of cardiovascular events.
Use of oral contraceptives is associated with 
a small but significant BP increase and develop-
ment of hypertension. However, most studies eval-
uated the effect of older generation contraceptives 
that contained a higher oestrogen dose than those 
currently used. Data are lacking regarding the ef-
fect of newer hormonal contraceptive methods 
(vaginal and transdermal) on BP but an associa-
tion was confirmed between newer contraceptive 
methods and an increased risk of venous thrombo-
sis. Progestin-only containing oral contraceptives 
(minipills) are not considered contraindicated in 
mild and moderate hypertension but they con-
stitute a minor proportion of currently used oral 
contraceptives.
Table XXV. Antihypertensive treatment strategies in women of reproductive age, during pregnancy and in the postpartum period, based on 
the PTNT/PTK/PTGP expert consensus statement (part 1)
In all women of reproductive age, lifestyle changes are recommended, in particular smoking cessation, limitation of alcohol intake, and body  
weight reduction
In hypertensive women of reproductive age, b-blockers and/or calcium antagonists should be considered
In hypertensive women of reproductive age, thiazide/thiazide-like diuretic may be considered
In women of reproductive age, substituting drugs typically used during pregnancy for regular chronic antihypertensive therapy may be considered 
already when planning pregnancy
Substituting drugs typically used during pregnancy for regular chronic antihypertensive therapy may be considered in women in whom use  
of assisted reproduction technology is planned.
During pregnancy, hypertension should be diagnosed if SBP is ≥ 140 mm Hg and/or SBP is ≥ 90 mm Hg in office measurements, confirmed 
by out-of-office measurements within 7 days in the first trimester and up to 2–3 days in the second and third trimester.
In pregnant women, it is recommended to maintain BP in the 110–140/80–85 mm Hg range
If SBP is ≥ 160 mm Hg and/or DBP is ≥ 110 mm Hg and/or symptoms are present that may suggest development of preeclampsia, it is recommen-
ded to refer the patient to a hospital
BP — blood pressure; DBP — diastolic blood pressure; SBP — systolic blood pressure
Table XXVI. Antihypertensive treatment strategies in women of reproductive age, during pregnancy and in the postpartum period, based 
on the PTNT/PTK/PTGP expert consensus statement (part 2)
In pregnant women with hypertension, first-line drugs include methyldopa, labetalol and extended release nifedipine
If a cardioselective b-blocker is indicated in pregnant women with hypertension, metoprolol should be considered
It is not recommended to use ACEI, ARB, renin inhibitors, and diltiazem during pregnancy (except for special clinical situations)
It is not recommended to use diuretics and spironolactone during pregnancy (except for special clinical situations)
Drugs indicated for emergency treatment of hypertension during pregnancy include intravenous labetalol, oral nifedipine, and intravenous hydralazine
The recommended rate of BP lowering during emergency treatment of hypertension it to reduce mean arterial pressure by not more than 25% 
during minutes/hours
In lactating women, use of labetalol or metoprolol or extended release nifedipine (or amlodipine) should be considered. Substituting other 
antihypertensive drugs for methyldopa should also be considered
In lactating women, use of ACEI, ARB, and diuretics is not recommended
In women at a high risk of preeclampsia (e.g., women with chronic hypertension or gestational hypertension during previous pregnancy), acetylsa-
licylic acid 100–150 mg once daily in the evening is recommended. The treatment should be started before 16 weeks of gestation and continued 
until 36 weeks of gestation
ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin receptor blocker; BP — blood pressure
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5.5. Hypertension in pregnant women
Taking into account pathophysiological, clinical 
picture, and management differences, the PTNT/ 
/PTK/PTGP expert consensus statement has divi-
ded hypertension during pregnancy into two major 
types:
• chronic (preexisting) hypertension: present be-
fore pregnancy or developing before 20 weeks 
of gestation and persisting usually beyond 6 or 
more weeks after delivery, which may be further 
subcategorised as:
— primary hypertension;
— secondary hypertension.
• gestational (pregnancy-induced) hypertension: 
developing after 20 weeks of gestation and usu-
ally resolving within 6 weeks after delivery, which 
may be further subcategorised as:
— gestational hypertension;
— preeclampsia.
Preeclampsia is a complication of placental dys-
function, and thus it develops mostly in the second 
half of pregnancy in pregnancy-induced hyperten-
sion but may also occur in women with preexisting 
hypertension, in whom BP elevation with other fea-
tures of preeclampsia are seen after 20 weeks of ges-
tation — this should be diagnosed as preeclampsia 
superimposed upon chronic hypertension.
Other serious complications of hypertension in 
pregnancy include the HELLP syndrome (clotting 
abnormalities, hepatic dysfunction, and low platelet 
count) and eclampsia or development of central 
nervous system dysfunction symptoms.
The principles of hypertension management in 
pregnant women, which have been discussed in 
detail in the above mentioned PTNT/PTK/PTGP 
expert consensus statement, are summarised in Ta-
bles XXV and XXVI.
5.6. Hypertension in patients with metabolic 
syndrome
Hypertension or high normal BP is a frequent com-
ponent of metabolic syndrome. Recommending life-
style changes, particularly body weight reduction and 
increased physical activity, is very important in all 
individuals with metabolic syndrome as the first and 
foremost intervention in the management of hyper-
tension. The aim is to reduce body weight by 7–10% 
over 6–12 months by modest reduction of caloric 
intake (by 500–1000 kcal per day) which is usually 
more effective than a more rigorous diet.
Indications for initiating drug therapy and tar-
get BP values do not differ from the general prin-
ciples of antihypertensive therapy considering the 
patient’s age. Currently, no evidence from outcome 
trials justifies initiation of drug treatment in pa-
tients with metabolic syndrome and high normal 
BP. Metabolic syndrome is associated with a high 
risk of developing diabetes, and thus the effect of 
antihypertensive drugs on glucose metabolism and 
the risk of new-onset diabetes which was evaluated 
in many clinical trials should be taken into consid-
eration when choosing antihypertensive drug classes. 
Drug therapy should be initiated with RAAS inhibi-
tors which delay development of diabetes, combined 
with a calcium antagonist or a thiazide-like diuretic 
and administered as SPC, or even a three-drug SPC 
if required. b-blockers and conventional thiazide di-
uretics should be avoided in patients with metabolic 
syndrome. If drugs from these classes are indicated, 
vasodilating b-blockers and thiazide-like diuretics 
should be chosen. When prescribing a diuretic, a po-
tassium-sparing preparation may be considered, as 
hypokalaemia worsens glucose tolerance.
5.7. Hypertension in diabetic patients
The prevalence of hypertension among diabetic pa-
tients is increased compared to the general popula-
tion. Masked hypertension is often present in dia-
betic patients, in particular nocturnal hypertension 
and a non-dipping circadian BP pattern. Another 
relatively frequent phenomenon is orthostatic hy-
potension due to autonomic neuropathy which is 
typical for diabetes. Thus, ABPM is recommended in 
each diabetic patient. BP should also be measured in 
the standing position in case of symptoms suggesting 
hypotension during therapy intensification.
Blood pressure lowering brings documented ben-
efits in regard to the reduction of mortality risk and 
the rates of all cardiovascular and renal complica-
tions (except for diabetic neuropathy). These ben-
efits are greater and more lasting compared to ben-
efits from good blood glucose control. In patients 
with hypertension and diabetes, antihypertensive 
drug therapy is typically recommended when BP 
is > 140/90 mm Hg. No evidence is available from 
outcome clinical trials that would justify initiating 
drug therapy in patients with diabetes and high 
normal BP, although use of a RAAS inhibitor in 
a substandard to standard dose is justified if micro- 
or macroalbuminuria is identified. Following the 
2018 ESC/ESH guidelines, we recommend target 
BP values in diabetes as in the general population 
of hypertensive patients, considering the patient’s 
age. This is mostly justified by the nephroprotective 
effect of antihypertensive treatment, although the 
SPRINT trial did not include diabetic patients, and 
the earlier 2012 ESH/ESC guidelines indicated that 
the optimal reduction of the global cardiovascular 
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risk in most patients with hypertension and diabetes 
was obtained by lowering BP below 140/85 mm Hg. 
This target DBP value was based on an analysis of 
HOT and UKPDS study findings, and in turn, ben-
efits of SBP lowering below 130 mm Hg in diabetic 
patients have not been confirmed in the ACCORD 
and INVEST studies.
Effective BP control in diabetic patients is dif-
ficult. Due to a proven nephroprotective effect of 
RAAS inhibitors, ACEI or ARB should be an invari-
able component of SPC. When choosing between 
ACEI and ARB in diabetic patients, results of the 
most recent metaanalysis of studies performed in 
this group of patients may be taken into consider-
ation, showing a greater long-term cardioprotective 
effect of ACEI. For combined therapy, first choices 
should include a RAAS inhibitor with a calcium an-
tagonist (ACCOMPLISH) or a thiazide-like diuretic 
(ADVANCE). The ADVANCE ON study results 
showed for the first time that antihypertensive therapy 
using a SPC (perindopril + indapamide) may yield 
long-term (10 years) outcome benefits in terms of 
a reduction of cardiovascular and all-cause mortality.
Concomitant administration of two RAAS in-
hibitors (also including the renin inhibitor) should 
be avoided due to a higher risk of hyperkalaemia 
and worsening of renal function (ONTARGET and 
ALTITUDE studies).
The management of patients with hypertension 
and diabetes should be particularly targeted at im-
provement of all cardiovascular risk factors. This 
means a strong indication for a statin, while acetyl-
salicylic acid (ASA) should not be used for primary 
prevention. The basic principles of the management 
of hypertension in diabetic patients are shown in 
Table XXVII.
A growing role of SGLT2 inhibitors (empa-
gliflosine, kanagliflosine, dapagliflosine) should be 
acknowledged, as these drugs improve cardiovascular 
outcomes, reduce the risk of heart failure, and show 
a clear BP-lowering effect in patients with diabetes.
5.8. Hypertension in patients  
with chronic kidney disease
Observational studies show a direct correlation be-
tween BP values and development of chronic kidney 
disease. Protection from further progression of renal 
disease requires strict BP control and reducing pro-
teinuria as much as possible, while the effect of re-
ducing albuminuria on the reduction of cardiovascu-
lar risk is not clear. Despite many studies and meta-
analyses on optimal target BP in this patient group, 
due to discordant conclusions from these analyses it 
seems reasonable to recommend target BP values as 
in the general population of hypertensive patients, 
considering the patient’s age (Table II). Lowering BP 
below 120/80 mm Hg to delay albuminuria is ques-
tionable (ROADMAP study), and in patients with 
hypertension and concomitant nephropathy with 
large proteinuria, this decision remains a domain of 
nephrologists.
Dietary salt restriction is a particularly important 
non-drug measure in these patients. Compared to 
other classes of antihypertensive medications, ACEI 
and ARB are more effective at reducing proteinuria 
and delaying progression of renal disease, and thus 
are indicated in patients with moderately reduced 
glomerular filtration rate and/or proteinuria. Ther-
apy should be started with low doses that are later 
cautiously increased to moderate ones, with eGFR 
and potassium level monitoring. Reduction of base-
line eGFR by 10–20% during the first 4–12 weeks 
of therapy should be considered acceptable. ACEI 
and ARB should not be used in patients with acute 
kidney injury, and initiation of these drugs is not 
recommended, unless supervised by a nephrologist, 
in patients with chronic kidney disease and eGFR 
below 30 mL/min/1.73 m2.
Table XXVII. Antihypertensive treatment strategies in patients with diabetes
Immediate drug therapy is recommended in patients with hypertension, and in those with high normal BP only if proteinuria is present
Target BP in patients with diabetes is < 130/80 mm Hg but specific BP targets in various age groups should be taken into account
The presence of proteinuria does not modify target BP
In diabetes, the preferred drugs are RAAS inhibitors (ACEI and ARB) due to a greater nephroprotective effect
The therapy is initiated with an SPC containing a RAAS inhibitor and dihydropyridine calcium antagonist or diuretic (thiazide-like agents are preferred)
If a b-blocker is required (due to cardiac disease), vasodilating agents seem more beneficial (due to a more favourable metabolic profile)
It is not recommended to combine two RAAS inhibitors
Statin therapy is recommended in diabetic patients
Acetylsalicylic acid is not recommended in diabetic patients without cardiovascular disease
ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin receptor blocker; BP — blood pressure; RAAS — renin-angiotensin-aldosterone system; SPC — single pill combination
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Combined antihypertensive therapy, optimally 
using SPC, is required to reach target BP values. 
Based on the results of the ACCOMPLISH study, 
it was shown that a combination of an ACEI with 
a calcium antagonist rather than a thiazide diuretic 
is more effective at preventing doubling of serum 
creatinine level and development of end-stage renal 
disease. The type and dose of a diuretic should be 
adjusted to renal function. Thiazide and thiazide-like 
diuretics should not be used in patients with eGFR 
below 30 mL/min, and loop diuretics should be used 
instead. Doses of loop diuretics should be increased 
with worsening of renal function.
In advanced chronic kidney disease, miner-
alocorticoid receptor antagonists are not recom-
mended, particularly in combination with a RAS 
inhibitor, due to a risk of renal function worsen-
ing and development of hyperkalaemia. If miner-
alocorticoid receptor antagonists are used in this 
patient group, strict potassium level monitoring 
is required. Combining two RAS inhibitors is also 
not recommended despite potentially higher ef-
fectiveness in reducing proteinuria. The latter two 
therapeutic options should remain a domain of 
nephrologists.
5.9. Hypertension in patients  
after solid organ transplantation
Hypertension is present in most patients after solid 
organ transplantation. These patients often show lack 
of nocturnal BP dipping or even a reverse dipper 
circadian BP profile. For these reasons, ABPM is 
particularly indicated in patients after solid organ 
transplantation.
The major causes of hypertension in patients 
after solid organ transplantation include use of BP 
elevation-inducing immunosuppressive drugs (glu-
cocorticosteroids and calcineurin inhibitors: ciclo-
sporin A and tacrolimus) and renal dysfunction. 
Use of ciclosporin A is associated with a higher 
degree of BP increase compared to tacrolimus use. 
Reversible vasospasm is the major mechanism of 
the pressor effect of calcineurin inhibitors. This 
particularly involves renal afferent arterioles, lead-
ing to a reduction of the glomerular filtration rate 
and to renal interstitial ischaemia. The management 
of hypertension may include all regular lifestyle 
modifications and use of all antihypertensive drug 
classes. In view of the mechanism of the pressor 
effect of calcineurin inhibitors, dihydropyridine cal-
cium antagonists should be preferred that have no 
effect on blood calcineurin inhibitor levels (nitren-
dipine, isradipine, lacidipine) or induce only slight 
elevation of these levels (amlodipine).
5.10. Hypertension complicated  
by ischaemic heart disease
Hypertension is an important factor in the patho-
genesis of ischaemic heart disease (accelerated ath-
erosclerosis, left ventricular hypertrophy), respon-
sible for 25% of its total risk. Each BP lowering by 
10 mm Hg reduces the risk of ischaemic heart disease 
by 17% regardless of baseline cardiovascular risk and 
the type of antihypertensive treatment used.
In hypertension with concomitant ischaemic heart 
disease, however, there is evidence suggesting exis-
tence of the J curve, or an increase in the coronary 
event risk with BP lowering below certain threshold. 
Two analyses suggested that SBP above 140 mm Hg 
and DBP above 80 mm Hg was associated with an 
increased risk of coronary event, but a similar in-
crease in risk was seen for SBP below 120 mm Hg 
and DBP below 70 mm Hg. For this reason, both the 
recommended target BP values and undesirable levels 
of BP reduction are the same as in uncomplicated 
hypertension.
Although optimal BP reduction is the most im-
portant factor for the reduction of ischaemic heart 
disease risk, the recommended antihypertensive 
drugs in patients with established ischaemic heart 
disease are ACEI (preferred drugs of this class are 
perindopril — EUROPA study, ramipril — HOPE 
study, and zofenopril — SMILE 4 study) and 
b-blockers (preferred drugs of this class are bisopro-
lol, due to cardioselectivity and effecting heart rate 
lowering, and nebivolol, due to cardioselectivity and 
nitric oxide generation), particularly in patients after 
a myocardial infarction. As the recommendation for 
using SPC as the first-line therapy is valid also in 
these patients, it should be noted that the combina-
tion of bisoprolol and perindopril is the only SPC 
available in Poland than contains drugs from both 
preferred classes. If angina is present, calcium an-
tagonists are also used. In patients with concomitant 
ischaemic heart disease, ARB are second-line drugs 
(preferred choices are telmisartan — ONTARGET 
study, and in patients after a myocardial infarction 
also valsartan — VALIANT study) in case of ACEI 
intolerance in patients with ischaemic heart disease, 
based on the results of multiple metaanalyses that 
compared these two drug classes in regard to the 
reduction of mortality and cardiac event risk.
It should be noted that the recommendations re-
garding drug therapy of stable coronary artery disease 
may be significantly modified in the future. This is 
related to new data regarding antiplatelet therapy 
regimens, new target LDL cholesterol levels, and 
introduction of the new term “chronic coronary syn-
dromes” to replace the previous term “stable coro-
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nary artery disease”. These changes are expected to 
take place in Europe in 2019. 
In this patient group, a particular role is played 
by so-called hybrid SPC [antihypertensive drug(s) 
+ statin] which are discussed in the section on lipid-
lowering therapy.
5.11. Hypertension complicated  
by heart failure
Along with ischemic heart disease, hypertension 
is one of the two major causes of heart failure. 
It often leads to left ventricular diastolic dysfunction 
and heart failure with preserved ejection fraction, in 
contrast to heart failure due to a previous coronary 
event, which is often associated with left ventricular 
systolic dysfunction and reduced ejection fraction. In 
both types of heart failure, hypertension is the most 
important modifiable risk factor for the development 
or progression of heart failure, and thus preventing 
heart failure involves use of antihypertensive drugs. 
Diuretics, b-blockers, ACEI, and ARB were shown 
to be beneficial, while calcium antagonists are not 
recommended.
In advanced heart failure, hypertension becomes 
less problematic due to reduction of cardiac output 
in this condition, and higher BP values are prognos-
tically favourable.
Indications for initiating antihypertensive therapy 
and target BP values are the same as in uncompli-
cated hypertension, but any antihypertensive therapy 
should be undertaken with consideration of the cur-
rent guidelines on the management of heart failure 
and the duration of the antihypertensive effect of 
specific drugs, which means that the preferred drugs 
in this patient group are b-blockers (only carvedilol, 
bisoprolol, metoprolol XR/CR, and nebivolol), 
ACEI (drugs studied in postinfarction left ventricular 
dysfunction include lisinopril, ramipril, trandolapril, 
and zofenopril), and aldosterone antagonists (eplere-
none is the preferred drug). ARB are second-choice 
drugs in case of ACEI intolerance (preferred drugs of 
this class are candesartan and valsartan). 
Diuretics are recommended in patients with 
clinical evidence of left- or right-sided heart fail-
ure. The preferred drugs are thiazide-like diuret-
ics with greater natriuretic effect (chlorthalidone) 
and loop diuretics, which induce an even stronger 
natriuretic effect (preferred torasemide). Among 
the latter, torasemide is characterised by greater 
bioavailability, better absorption, and longer half-
life compared to furosemide, and exerts an ad-
ditional anti-aldosterone effect, which translated 
to increased clinical benefits observed in the non-
randomised TORIC study.
5.12. Hypertension complicated  
by atrial fibrillation
Hypertension (and even high normal BP) predis-
poses to the development of atrial fibrillation. Due to 
frequent presence of asymptomatic atrial fibrillation 
in hypertensive patients, this arrhythmia should be 
actively searched for in this patient population. It 
has been estimated that atrial fibrillation is present in 
about 500,000 people in Poland. In this population, 
hypertension is present in nearly 80% of subjects. It 
is thus believed that hypertension is a major underly-
ing factor in the vast majority of patients with atrial 
fibrillation. Hypertension leads to left ventricular 
hypertrophy and overload, increased left atrial vol-
ume and wall tension, and activation of the RAAS 
and the sympathetic nervous system, all resulting in 
electrical, structural, and neurohormonal remodel-
ing of cardiomyocytes, which is a substrate for atrial 
fibrillation. 
Major diagnostic and therapeutic challenges in 
this patient group include difficulties in diagnosing 
hypertension in patients with persistent and perma-
nent atrial fibrillation, decisions regarding initiation 
of anticoagulant therapy, and antihypertensive ther-
apy in patients w hypertension and atrial fibrillation.
Atrial fibrillation is a frequent cause of errors in 
BP measurement. The arrhythmia is associated with 
varying left ventricular filling times and stroke vol-
ume, which results in a large variability of BP values 
and low reproducibility of BP measurements. These 
limitations also hold true for ABPM. In this pa-
tient population, caution should be exercised when 
diagnosing hypertension based on only HBPM or 
ABPM, despite a class I recommendation for these 
methods for the diagnosis of hypertension in the 
ESC/ESH guidelines. Precise ascertainment of BP 
values in patients with atrial fibrillation is very im-
portant as it often underlies the decision to initi-
ate anticoagulation. If BP is > 140/90 mm Hg in 
two measurements during at least two visits or the 
patient receives antihypertensive therapy, anticoagu-
lation should be considered even if there are no 
other risk factors for thromboembolism (class IIa 
recommendation). Individual patient characteristics 
and preferences should also be taken into account. 
In these case, the criteria for the diagnosis of hyper-
tension according to the European guidelines should 
be followed. If hypertension is accompanied by other 
risk factors for stroke including heart failure, age 
65 years or above, vascular disease, diabetes, female 
gender, and a history of stroke/TIA, anticoagula-
tion should be started (class I recommendation). 
When initiating anticoagulation, non-vitamin K 
oral anticoagulants (NOAC), including apixaban, 
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dabigatran, rivaroxaban and edoxaban (the latter 
not available in Poland), are preferred over warfarin 
and acenocoumarol. No data are available to indi-
cate an advantage of any particular NOAC over the 
others in patients with hypertension. Renal func-
tion should be monitored during treatment with 
NOAC. Hypertension is not only an important risk 
factor for thromboembolic complications in patients 
with atrial fibrillation but also the most important 
modifiable risk factor for bleeding in patients with 
atrial fibrillation receiving anticoagulant therapy, 
particularly if SBP is above 160 mm Hg. Prevention 
of bleeding complications in this patient population 
involves careful BP control with values below 140/90 
mm Hg, and preferably below 130/80 mm Hg. In 
most patients with hypertension and atrial fibrilla-
tion, the latter is associated with a rapid ventricular 
rate and b-blockers or non-dihydropyridine calcium 
antagonists (verapamil, diltiazem) are recommended. 
When choosing a b-blocker, the effect on slowing 
conduction at the atrioventricular junction should 
be taken into account, and this bisoprolol might 
be more beneficial than vasodilating b-blockers. 
Of note, SPC are available (b-blocker + other antihy-
pertensive drug) that allow both BP and ventricular 
rate control. Non-dihydropyridine calcium antago-
nists are not recommended in patients with impaired 
left ventricular systolic function.
In those patients, b-blocker should be used for ef-
fective ventricular rate control, with digoxin added if 
required. In patients with hypertension, left ventricu-
lar hypertrophy, and high cardiovascular risk, RAAS 
inhibitors delay occurrence of the first atrial fibrillation 
episode, but these drugs do not prevent arrhythmia 
recurrence in patients with paroxysmal or persistent 
atrial fibrillation. In patients with atrial fibrillation, 
the choice of antihypertensive therapy is also deter-
mined by concomitant conditions such as coronary 
artery disease, heart failure, diabetes, chronic kidney 
disease, advanced age, and obesity. The choice of the 
therapy may also be dictated by further therapeutic 
plans regarding the management of arrhythmia itself. 
With higher recommendation class and increasing 
availability of electrophysiological procedures (abla-
tion of the atrial fibrillation substrate), the importance 
of antiarrhythmic drugs (amiodarone, propafenone, 
sotalol) used to control ventricular rate is decreasing. 
Propafenone should not be used in patients with se-
vere organic heart disease, while sotalol should not be 
used in patients with left ventricular hypertrophy, and 
verapamil and diltiazem should not be used in those 
with reduced left ventricular ejection fraction.
In summary, asymptomatic atrial fibrillation should 
actively searched for in patients with hypertension.
Anticoagulation with the preference of NOAC 
should be considered in all patients with hyperten-
sion and atrial fibrillation.
The management of hypertension in patients with 
concomitant atrial fibrillation is consistent with the 
general principles for hypertensive patents. Effec-
tive BP control in patients with atrial fibrillation 
receiving anticoagulant therapy prevents both isch-
aemic and haemorrhagic strokes. SPC containing a 
b-blocker and another antihypertensive drug should 
be preferred.
High bleeding risk is not a contraindication for 
anticoagulation but risk factors for bleeding should 
be reduced (BP control, time in therapeutic range 
> 70% when using vitamin K antagonists, avoidance 
of non-steroidal anti-inflammatory and antiplatelet 
drugs, limiting alcohol intake).
The basic principles of the management of hyper-
tension in patients with cardiac complications are 
shown in Table XXVIII.
5.13. Hypertension and prevention of stroke
Regardless of the type of therapy, effective BP low-
ering reduces stroke risk more effectively than the 
risk of ischaemic heart disease. Metaanalyses indi-
cate, however, that b-blockers are less effective and 
calcium antagonists are more effective at reducing 
stroke risk compared to other antihypertensive drug 
classes, although the data for b-blockers are based on 
atenolol and not modern cardioselective b-blockers, 
let alone the vasodilating ones.
Within 1–2 weeks (several days according to 
the 2018 ESC/ESH guidelines) after a stroke, 
and earlier after a TIA, BP normalisation should 
be sought according to the general management 
principles (target BP < 130/80 mm Hg should 
be reached slowly, and provided that treatment 
is well tolerated). The reported data indicate ef-
ficacy of thiazide-like diuretics (indapamide in 
the PATS study and combined with perindopril 
in the PROGRESS study) and ARB (eprosartan 
in the MOSES study) in the secondary prevention 
of stroke, although target BP in all these studies 
was < 140/90 mm Hg. Results of a more recent 
study on lacunar strokes suggest benefits from BP 
lowering below 130/80 mm Hg. During each visit, 
BP should be measured in the standing position to 
avoid excessive BP falls.
The effect of antihypertensive drug therapy on 
the severity of vascular dementia has not been clearly 
documented. One metaanalysis suggested that an-
tihypertensive treatment was associated with a 9% 
reduction in the risk of incident dementia and cogni-
tive dysfunction.
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Due attention should also be paid to other basic 
elements of secondary stroke prevention, such as 
lifestyle modification and treating risk factors, anti-
coagulation, use of antiplatelet agents, and surgical 
treatment of carotid artery stenosis.
Results of few studies on antihypertensive therapy 
in the acute phase of stroke are equivocal. It is be-
lieved that regardless of the stroke type, BP should be 
lowered in the acute phase of stroke only if SBP ex-
ceeds 220 mm Hg and/or DBP exceeds 120 mm Hg, 
and the drug if choice in these circumstances is labet-
alol (or, if it is unavailable, intravenous agents with 
a medium duration of action). BP should be slowly 
reduced to values about 170–180/110 mm Hg. In 
the SCAST study, no significant effect of antihyper-
tensive drug therapy in the acute phase of stroke was 
found on cardiovascular events, including recurrent 
stroke.
Fibrinolytic therapy may be used if BP is lower 
than 185/110 mm Hg. On the second day after 
stroke, antihypertensive therapy may be initiated if 
BP is higher than 180 and/or 120 mm Hg.
The basic principles of the management of hy-
pertension in patients after a stroke are shown in 
Table XXIX.
5.14. Other concomitant conditions
5.14.1. Hypertension with sexual dysfunction
Erectile dysfunction is more common in hyperten-
sives than in individuals with normal BP values. 
Sexual dysfunction impairs patients’ quality of life 
and is considered an independent cardiovascular risk 
factor and an early marker of atherosclerosis. At the 
same time, sexual dysfunction developing during 
antihypertensive therapy is a significant factor that 
has a negative effect on treatment compliance and 
persistence.
Multiple studies showed that antihypertensive 
drug therapy using older generation diuretics and 
b-blockers increases the risk of erectile dysfunction 
in men. Compared to these drugs, newer antihyper-
tensive drug classes, i.e. ARB and ACEI, have a neu-
tral or even beneficial effect on erectile function. If 
a b-blocker is needed, nebivolol is preferred, as in 
Table XXVIII. Antihypertensive treatment strategies in patients with cardiac disease
Antihypertensive therapy is indicated in grade ≥ 1 hypertension, and target BP in patients with heart disease is < 130/80 mm Hg
Due to a possibility of the J-curve effect, the recommendation to avoid BP lowering to < 120/70 mm Hg is particularly important in patients 
with ischaemic heart disease
In patients with high normal BP, antiihypertensive drugs used for the treatment of ischaemic heart disease/heart failure are recommended 
but without the need for achieving target BP values
Preferred antihypertensive drugs in patients with ischemic heart disease are ACEI and b-blockers, particularly after a myocardial infarction, 
and in patients with angina also calcium antagonists
Preferred antihypertensive drugs in patients with heart failure are ACEI and b-blockers, followed by aldosterone antagonists (preferred eplerenone), 
and diuretics with evidence of volume overload
In patients with ischemic heart disease and/or heart failure, ARB are alternative second choice drugs in case of ACEI intolerance
In patients with atrial fibrillation with rapid ventricular response, b-blockers or possibly non-dihydropyridine calcium antagonists are recommended 
as antihypertensive drugs
Every hypertensive patient with atrial fibrillation requires antithrombotic treatment, preferentially with a novel oral anticoagulant
Every hypertensive patient with heart disease requires statin and acetylsalicylic acid
In patients with a risk of de novo or recurrent atrial fibrillation, ACEI or ARB may be considered for antihypertensive drug therapy, and eplerenone 
may be considered in patients with concomitant heart failure
ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin receptor blocker; BP — blood pressure
Table XXIX. Antihypertensive treatment strategies in stroke patients
Target BP in patients after a stroke or TIA is < 130/80 mm Hg or < 140/90 mm Hg depending on patient age. Target BP values should be reached 
slowly, about 2 weeks after the acute event, provided that the treatment is well tolerated
Antihypertensive drug therapy for the secondary prevention of stroke should be based on an ARB or a thiazide-like diuretic (indapamid)  
with a possible addition of an ACEI
Other major components of secondary prevention are indicated, such as lifestyle changes and treatment of risk factors, anticoagulant and antiplate-
let treatment, and surgical treatment of carotid artery disease (if indicated)
In the acute phase of stroke, treatment of hypertension is indicated only for BP > 220/120 mm Hg
ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin receptor blocker; BP — blood pressure; TIA — transient ischemic attack
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contrast to conventional b-blockers, nebivolol exerts 
a vasodilatatory effect related to nitric oxide release. 
Several studies showed that nebivolol may have a less 
effect on erectile dysfunction in men.
5.14.2. Hypertension and chronic obstructive 
pulmonary disease
Concomitant presence of hypertension and COPD 
is associated with a significantly increased cardio-
vascular risk. No studies compared the effect of 
antihypertensive therapy using different drug class-
es on long-term outcomes in patients with con-
comitant COPD. However, the mechanism of ac-
tion of some antihypertensive drug classes calls for 
caution when using ACEI (bradykinin-mediated 
mechanism, cough inducing bronchospasm) and 
b-blockers (bronchospasm, reduced lung ventila-
tion parameters, attenuated effect of b-agonists). 
If a drug from the latter class is required, its choice 
must be carefully dictated by cardioselectivity or ad-
ditional protective properties, and attention must be 
paid to the recommended dose to minimise the ef-
fect on lung ventilation parameters. Cardioselective 
b-blockers were found to reduce mortality among 
patients with COPD and concomitant cardiac dis-
ease. Fewer concerns are associated with diuretic 
use (an effect synergistic with that of COPD itself, 
resulting in metabolic alkalosis and hypokalaemia, 
similarly to glucocorticosteroids and b-agonists, 
thickening of bronchial secretions). Safe antihyper-
tensive drugs in patients with COPD include cal-
cium antagonists and ARB. 
5.14.3. Hypertension and glaucoma
The recommendations for coexisting hypertension 
and glaucoma have not been changed compared to 
the 2015 PTNT guidelines. The safest antihyper-
tensive drugs that are not associated with a risk of 
glaucoma incidence and progression are b-blockers.
Among the risk factors for glaucoma, in addition 
to high BP, an increasing attention has been paid to 
systemic hypotension which may lead to reduced 
perfusion of the optic disc and induce glaucoma le-
sions. It seems that systemic hypotension is a much 
more important risk factor for progression of visual 
field defects than hypertension. Thus, overly ag-
gressive antihypertensive therapy may lead to pro-
gression of glaucoma. Most importantly, adverse 
effects of antihypertensive therapy include excessive 
nocturnal BP fall with secondary reduction of ocu-
lar perfusion. In patients with glaucoma, evening 
dosing of antihypertensive drugs is contraindicated 
unless ABPM shows very high BP values during the 
night.
5.14.4. Hypertension and gout
An antihypertensive agent that reduces hyperuricae-
mia is losartan (this might have been of an impor-
tance for cardiovascular risk reduction in the LIFE 
study), but due to short duration of action and low 
availability in SPC, this drug is no longer considered 
the preferred choice for antihypertensive therapy in 
patients with concomitant gout. There are no contra-
indications for other ARB, ACEI, and calcium antag-
onists in patients with hyperuricaemia. In contrast, 
use of drugs that increase serum acid level, mostly 
thiazide/thiazide-like diuretics and b-blockers, is 
not advised. Allopurinol use, previously reserved for 
chronic secondary prevention of gout attacks, has 
become more common in hypertensives at high car-
diovascular risk with asymptomatic hyperuricaemia 
(see chapter 6.3, uric acid-lowering therapy).
5.14.5. Hypertension and benign prostatic 
hyperplasia
When treating hypertension in men with benign 
prostatic hyperplasia, the general principles of anti-
hypertensive therapy in the elderly using major drug 
classes should apply, and the previous recommenda-
tion to initiate therapy with an a-blocker has been 
abandoned after the ALLHAT study. The decision 
to use an alpha1-adrenergic receptor antagonist to 
improve micturition should be made by an urolo-
gist, with consideration of uroselective drugs (e.g., 
tamsulosin) for better cardiac safety in patients on 
established antihypertensive therapy. Non-selective 
alpha1-blockers (e.g., doxazosin) are among useful 
fourth- and fifth-line antihypertensive drugs in resis-
tant hypertension (ASCOT, PATHWAY-2).
5.14.6. Hypertension and psoriasis
The prevalence of hypertension in patients with pso-
riasis is increased compared to the general popula-
tion, as it’s resistance to treatment. The pathogenesis 
of hypertension in patients with psoriasis is related, 
among other factors, to systemic inflammation. 
b-blockers should be avoided in hypertensives with 
psoriasis and no concomitant ischaemic heart dis-
ease, as these drugs may worsen psoriasis.
5.14.7. Hypertension in the perioperative period
Grade 1 and 2 hypertension does not require post-
poning a surgical procedure. In contrast, surgery 
should be postponed, unless it is urgent, until BP 
normalisation in a patient with grade 3 hyperten-
sion. Preoperatively, it is not desirable to aim for full 
BP normalisation by intensifying previous therapy. 
Target BP values may be in the range of 140–160/ 
/90–100 mm Hg (due to an additional BP-lowering 
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effect of anaesthetics). However, large BP variation in 
the perioperative period should be avoided.
Previous antihypertensive drug therapy should be 
generally continued, with usual morning dose of 
most BP-lowering drugs. If possible, withholding 
diuretics 2–3 days before a major surgery should be 
considered (due to potential adverse effects related 
to fluid loss and hypokalaemia), and possibly also 
RAAS inhibitors on the day of the surgery (with the 
last dose taken on the day before the surgery). In the 
recent years, controversies have arisen around the 
use of b-blockers in the perioperative period. Po-
tential benefits of these drugs are limited to patients 
with a history of myocardial infarction or with heart 
failure, and thus patient populations in which long-
term use of b-blockers is indicated anyway. In other 
patients, initiating b-blocker therapy, particularly 
several days before the surgery, may be associated 
with an increased mortality risk. In the recent ESC 
guidelines, more consideration has been given to 
perioperative statin than b-blocker use.
5.14.8. Hypertension in cancer patients
Hypertension is the most common cardiovascular di-
agnosis in cancer patients, present in one in three pa-
tients in this population. This is related not only with 
the prevalence of hypertension in specific age groups 
but also with the use of two widely implemented an-
ticancer drug classes: VEGF pathway inhibitors (be-
vacizumab, sorafenib, sunitinib, pazopanib) and pro-
teasome inhibitors (carfilzomib). The former inhibit 
nitric oxide production in the arterial wall, and the 
latter reduce vasodilatatory response to acetylcholine, 
favoring vasospasm over vasodilation. BP increase is 
observed in up to 30% of patients treated with these 
drugs, often during the first months of therapy. In 
patients who developed hypertension and those with 
DBP increase by 20 mm Hg or more compared to 
pretreatment values, antihypertensive therapy should 
be initiated or intensified, and the preferred drugs are 
RAAS inhibitors and calcium antagonists.
Among the latter, dihydropyridines should be used, 
as the non-dihydropyridine agents (diltiazem, vera-
pamil) block CYP3A4 isoenzyme which is involved in 
the metabolism of, e.g., sorafenib, which may increase 
blood level of the latter or even lead to its direct toxic-
ity. Evidence from preclinical (captopril, perindopril, 
zofenopril) and clinical (perindopril) studies on anti-
cancer activity of ACEI support not only safety and 
but also additional benefits of ACEI in the treatment 
of hypertension in cancer patients.
With advances in oncological treatment and a gen-
eral outcome and survival improvement in many ma-
lignancies, chronic antihypertensive therapy, similar-
ly to that in other patients with hypertension, should 
be preferably undertaken with newer drugs, free from 
some adverse effects that characterise the older drugs.
5.15. Resistant hypertension
The management algorithm in patients with sus-
pected resistant hypertension is shown in Figure 8.
Resistant hypertension is defined as inadequate 
BP control (BP values persistently ≥140/90 mm Hg) 
during appropriate combination therapy with 3 drugs 
(including a diuretic) in adequate doses, confirmed 
by ABPM and after patient non-compliance has been 
excluded.
With this definition, resistant hypertension is 
a common clinical problem. Due to lowered target 
BP values (< 130/80 mm Hg), it is worth considering 
a change of this definition, with the new definition 
as follows: persistence of BP values ≥ target values 
for given patient age when using 4 drugs, including 
an aldosterone antagonist. This change has not been 
made in the present guidelines to retain consistency 
with the 2018 ESC/ESH guidelines. In Poland, the 
proportion of patients with resistant hypertension 
has been estimated at 10–13% of all treated hyper-
tensives. With lower target BP values, this proportion 
would be higher. Patients with resistant hypertension 
are characterised by an increased cardiovascular risk 
compared to those with well controlled BP. Cardio-
vascular risk is also related to the number of antihy-
pertensive drugs used.
Most commonly, pseudoresistance to treatment is 
observed due to the following reasons:
 — non-compliance;
 — inappropriate drug treatment — too low drug 
doses, drug combinations including no diuretic;
 — BP increase in office measurements (white coat 
effect);
 — errors during BP measurement;
 — pseudohypertension.
The most common identifiable and often correct-
able reasons for treatment resistance include:
1. Lack of appropriate lifestyle modifications, in-
cluding body weight increase and consumption 
of large amounts of alcohol.
2. Taking medications and substances that raise BP 
(e.g., non-steroidal anti-inflammatory drugs, glu-
cocorticosteroids, cocaine, licorice etc.).
3. Undiagnosed secondary hypertension. Common 
causes include obstructive sleep apnoea, renal 
disease, primary hyperaldosteronism, and renal 
artery stenosis.
4. Volume overload due to inappropriate diuretic 
treatment, progressive renal dysfunction, and 
large sodium intake.
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5. Advanced, irreversible vascular damage leading 
to a significant increase in the arteriolar wall- 
-to-lumen ratio or reduced large artery com-
pliance.
After excluding these often difficult-to-eliminate 
causes, the prevalence of true resistant hypertension 
is much lower. In patients with true resistant hyper-
tension, SBP values are usually very high, and the 
prevalence of severe left ventricular hypertrophy and 
renal dysfunction is increased.
5.15.1. Drug therapy of resistant hypertension
The recommended and effective three-drug combi-
nation includes a RAAS inhibitor, thiazide/thiazide-
like diuretic, and a calcium antagonist, preferably as 
a SPC. In some patients with resistant hypertension, 
changing previous medications to this three-drug 
combination may be associated with improved BP 
control. In resistant hypertension, a good response 
has been observed to a mineralocorticoid receptor 
antagonist as the next treatment step, particularly 
spironolactone, even in low doses of 25–50 mg/day. 
The PATHWAY-2 study showed that treatment with 
spironolactone was associated with a greater BP-low-
ering effect compared to bisoprolol or doxazosin use. 
If spironolactone is not tolerated, eplerenone may be 
used instead. BP lowering in response to administra-
tion of an aldosterone antagonist may be attributed 
to lowering aldosterone level, which is often elevated 
in resistant hypertension due to a re-increase in aldo-
Conrm resistant hypertension
Ofce BP ≥� 140/90 mm Hg in a patient who has been 
prescribed 3 antihypertensive drugs in full doses, 
including a diuretic
Screen for secondary hypertension
— obstructive sleep apnoea (snoring, excessive daytime 
     somnolence)
— primary aldosteronism (spontaneous hypokalaemia, 
     muscle weakness)
— chronic kidney disease (creatinine clearance > 30 mL/min)
— renal artery stenosis (young women, presence 
     of atherosclerosis, renal function impairment)
— phaeochromocytoma (paroxysmal hypertension, palpitations, 
     headache)
— Cushing syndrome (moon face, central obesity, striae)
— coarctation of the aorta (brachial-femoral artery pulse 
     difference, systolic murmur)
Intensication of drug treatment
— add an aldosterone antagonist (spironolactone)
— add or substitute a loop diuretic (torasemide), particularly 
     in patients with chronic kidney disease and/or evidence 
     of sodium and water retention
— add an alpha-blocker and/or a beta-blocker
— use drugs with different mechanisms of action, 
     administered twice daily
Refer to a specialist
— if secondary hypertension is suspected, if hypertension 
     remains uncontrolled after 6 months of therapy
Specialist hypertension units
— conrmation/exclusion of secondary hypertension
— further intensication of drug treatment in a hypertension 
     clinic
— consideration of renal denervation in a tertiary care 
     referral unit
Exclude pseudoresistance to treatment
Is the patient compliant with treatment recommendations?
Evaluation of home BP values, exclusion of white coat 
effect based on ABPM
Modify reversible lifestyle factors
Obesity, lack of physical activity, excessive alcohol 
and salt intake, low-bre diet
Eliminate or minimize drug interactions
Nonsteroidal anti-inammatory drugs
Sympathomimetic agents
Stimulants
Oral contraceptives
Licorice, illicit drugs
Rycina 8. Management algorithm in suspected resistant hypertension. BP — blood pressure
2019 Guidelines for the Management of Hypertension
81www.ah.viamedica.pl
sterone release following its initial reduction induced 
by RAAS inhibition, or due to unrecognised mild 
primary hyperaldosteronism. The next treatment 
step should be to use a loop diuretic, particularly 
torasemide, in addition to or instead of a thiazide/
thiazide-like diuretic, with such substitution particu-
larly in patients with renal dysfunction, and obliga-
torily in patients with eGFR < 30 mL/min/1.73 m2. 
Further treatment intensification includes adding an 
alpha1-blocker (doxazosin) or a b-blocker (bisopro-
lol). In regard to the choice of a b-blocker, a vasodi-
lating b-blocker may also be considered (nebivolol at 
the dose of 10 mg). Of note, some older generation 
antihypertensive drugs may be effective in the treat-
ment of resistant hypertension, i.e., direct arterial 
vasodilators (hydralazine) and central sympatholytic 
drugs (clonidine). In resistant hypertension, twice 
daily dosing of antihypertensive drugs is frequently 
necessary.
The algorithm for the management of resistant 
hypertension is shown in Table XXX.
5.16. Renal artery ablation (renal denervation)
Experimental and clinical studies indicate that dam-
age to afferent and efferent renal nerves has a ben-
eficial effect on the pathophysiological mechanisms 
that contribute to the pathogenesis of hyperten-
sion, ultimately leading to BP lowering. Results of 
the pilot Symplicity HTN-1 study and the ran-
domised Symplicity HTN-2 study showed that re-
nal denervation was very effective at controlling BP 
in patients with resistant hypertension. However, 
based on the degree of renal denervation as eval-
uated by renal noradrenaline release, only partial 
(47%) effectiveness of the procedures was shown. 
The BP-lowering effect of renal denervation was 
questioned after publication of the large Symplic-
ity HTN-3 study results, conducted in the United 
States in patients with resistant hypertension who 
were randomised to renal denervation or a sham 
procedure. At 6 months of follow-up, no signifi-
cant difference in BP lowering was seen between 
the groups. A careful analysis of the study protocol 
and conduct showed many significant limitations of 
this study (e.g., inadequate experience in perform-
ing renal denervation, as indicated by the fact that 
111 operators were performing these procedures 
in 88 centres in the United States, modification of 
antihypertensive drug therapy in 40% of patients 
before the primary endpoint was analysed, incom-
plete renal artery ablation in 70% of the treated 
patients, and no methods to verify the effectiveness 
of renal denervation) which are believed to contrib-
ute significantly to no difference in SBP between 
the study group and the control group. At the same 
time, autopsy studies were published which showed 
a large interindividual variation of renal innervation 
and a higher effectiveness of those procedures which 
involved the whole vessel circumference, main renal 
arteries including the distal part of the artery with 
its branches, and accessory renal arteries, which may 
be challenging in terms of the available renal abla-
tion catheters and their size in relation to the vessel 
size. The randomised PRAGUE-15 study showed 
that renal denervation is equally effective at lower-
ing BP as adding spironolactone but a subanalysis 
of this study showed that 39% of patients did not 
tolerate spironolactone treatment, and this propor-
tion is higher compared to the usually reported rates 
of adverse effects during this treatment (10–30%). 
Another randomised DENERHTN study showed 
an advantage of renal denervation in terms of BP 
reduction (by 5.9 mm Hg) in patients with resistant 
hypertension compared to the control group, with 
the same antihypertensive drug therapy regimen 
used in both groups. Results of these studies and 
Table XXX. Antihypertensive treatment strategies in patients with resistant hypertension
Pseudoresistance should be excluded, correctable causes of treatment resistance should be eliminated, and compliance should be confirmed  
before institution of additional therapy
In patients who are unsuccessfully treated with a RAAS inhibitor, thiazide-like/thiazide diuretic, and calcium antagonist in maximal doses,  
an aldosterone antagonist should be added (spironolactone 25–50 mg/d)
The next step should be to add or substitute a loop diuretic (torasemide 10–20 mg/d), particularly in patients with severe kidney dysfunction
The next step should be to add an a-blocker (doxazosin 4–8 mg/d) or a b-blocker (bisoprolol 5–10 mg/d). A vasodilating b-blocker 
may be considered (nebivolol 10 mg/d)
As the next step, addition of a direct arteriolar vasodilator (hydralazine) or a central acting agent (clonidine) should be considered
In exceptional cases of truly resistant hypertension, after all the above drug treatment measures have been tried, invasive treatment  
(renal denervation) may be considered
Patient selection for renal denervation should be a domain of hypertension specialists, and these procedures should be performed by invasive  
cardiologists in specialized centres
RAAS — renin-angiotensin-aldosterone system
arterial hypertension 2019, vol. 23, no. 2
82 www.ah.viamedica.pl
new insights on the anatomy of renal arteries were 
taken into account in the protocols of the 2.0 gen-
eration trials (SPYRAL HTN-ON MED, SPYRAL 
HTN-OFF MED, and RADIANCE-HTN SOLO), 
in which patients were randomised to renal denerva-
tion or sham procedures. For the SPYRAL HTN- 
-OFF study, patients were recruited with office SBP 
150 mm Hg or more but not above 180 mm Hg and 
DBP 90 mm Hg or more (confirmed by ABPM) 
who did not receive antihypertensive medications or 
in whom drugs could be completely discontinued. 
At 3 months of follow-up, a difference in BP lower-
ing by ABPM was found between the groups in fa-
vour of the renal denervation group (24-hour mean 
SBP –5.0 mm Hg, 24-hour mean DBP –4.4 mm 
Hg). The same baseline BP values were the entry 
criteria in the SPYRAL HTN-ON MED study but 
patients received 1–3 antihypertensive drugs for at 
least 6 weeks. At 6 months of follow-up, denervation 
of main renal arteries and their branches resulted in 
more pronounced SBP and DBP lowering compared 
to the sham procedure (mean between-group dif-
ferences by ABPM: 24-hour mean SBP –7.4 mm 
Hg, 24-hour mean DBP –4.1 mm Hg). Procedure-
related adverse effects were not observed in either 
study. Of note, the proportion of patients compliant 
with drug therapy did not exceed 60%, as evaluated 
by laboratory tests for the presence of recommended 
medications.
In contrast to use of the four-electrode Symplicity 
catheter which allows radiofrequency current abla-
tion, renal denervation in the RADIANCE-HTN 
SOLO study involved ultrasound ablation of the re-
nal arterial system. The study included hypertensive 
patients with BP below 170/105 mm Hg off drugs, 
in whom up to 1–2 antihypertensive medications 
were previously used and discontinued 4 weeks ear-
lier. At 2 months of follow-up, daily SBP lowering by 
ABPM was –8.5 mm Hg in the denervation group 
compared to –2.2 mm Hg in the control group. Dur-
ing further follow-up, between 2 and 5 months after 
the procedure, patients with BP persistently above 
135/85 mm Hg in home measurements received am-
lodipine, followed by addition of an ACEI or ARB, 
and ultimately hydrochlorothiazide if required. At 
6 months of follow-up, the proportion of patients 
requiring drug therapy was lower in the denerva-
tion group (65.2%) compared to the control group 
(84.5%).
In the denervation group, daily SBP lowering 
was more pronounced compared to the sham proce-
dure group (–18.1 ± 12.2 vs. –15.6±.13.2 mm Hg, 
P = 0.024). Results of the SPYRAL and RADIANCE-
HTN trials were not available at the time the 2018 
ESC/ESH guidelines were prepared, and thus renal 
denervation received a class III recommendation in 
the European guidelines (not recommended as a rou-
tine procedure in the management of hypertension). 
Results of pilot studies indicate a beneficial effect of 
renal denervation on the improvement of the gly-
caemic profile, the apnoea-hypopnea index (AHI) 
in patients with obstructive sleep apnoea, and renal 
function in patients with chronic kidney disease. 
Currently, pending confirmation of the long-term 
effectiveness of renal denervation, it is recommended 
that patient selection for this procedure should be 
limited to specialised hypertension units, and these 
procedures should be performed by experienced in-
vasive cardiologists.
5.17. Life-threatening conditions
Conditions that require a rapid intervention due 
to high BP values (≥ 180 and/or 120 mm Hg) may 
be categorised into hypertensive emergencies and 
urgencies.
5.17.1. Hypertensive emergencies
In hypertensive emergencies, severe BP elevation is 
associated with acute complications that are immedi-
ately life-threatening. Typical presentations include:
1. Malignant hypertension — usually grade 3 hy-
pertension with advanced retinopathy (haemor-
rhages and/or papilloedema on fundoscopy), mi-
croangiopathy and disseminated intravascular co-
agulation, and in some cases also with encephalop-
athy, acute heart failure, and acute kidney injury. 
The hallmark of this condition is fibrinoid necrosis 
within small arteries and arterioles in the kidneys, 
retina, and brain. The term “malignant” suggests 
very poor outcomes without adequate treatment.
2. Severe hypertension associated with other life-
threatening conditions (myocardial infarction, 
acute coronary syndrome, pulmonary oedema, 
stroke, head trauma, aortic dissection). 
3. Sudden severe BP elevation in patients with 
phaeochromocytoma. 
4. Severe hypertension or preeclampsia in preg-
nant patients.
Symptoms and signs of hypertensive emergencies 
depend on the affected organs but common mani-
festations include headache, vision disturbances, 
chest pain, dyspnoea, dizziness, and neurological 
deficits. In patients with hypertensive encephalopa-
thy, excessive sleepiness, lethargy, tonic seizures, 
and cortical blindness may precede loss of con-
sciousness. Focal neurological signs are rare and 
should always raise a suspicion of stroke. Diagnos-
tic tests recommended in patients with suspected 
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hypertensive emergencies are listed in Table XXXI. 
In these circumstances, admission to an intensive 
care unit is required and parenteral antihyperten-
sive therapy is often necessary. The management 
of hypertensive emergencies depends on the type 
of target organ damage, ranging from only very 
cautious BP reduction in acute stroke to immediate 
BP reduction in acute pulmonary oedema or aortic 
dissection. In most cases, immediate BP reduction 
is suggested, with the target of BP lowering by 25% 
within first hours of treatment using available par-
enteral antihypertensive medications (Tab. XXXII). 
Except for urgent BP lowering in stroke, there are 
no randomised trials that would evaluate various 
management strategies in patients with hyperten-
sive emergencies. The most important factors to 
consider when planning the management strategy 
include:
 — evaluation of the presence of target organ damage 
(and whether they require specific management 
in addition to BP lowering); 
 — recommended timing and degree of BP lowering; 
 — required mode of BP lowering — regarding med-
ications, the ideal drug in hypertensive emergen-
cies is administered intravenously, has a short 
half-life, and allows cautious BP reduction un-
der strict physician supervision with continuous 
monitoring of the haemodynamic status; 
Table XXXI. Diagnostic tests recommended in patients with suspected hypertensive emergencies
Basic tests regardless of a potential cause
Haemoglobin, platelet count, fibrinogen
Electrolytes
Creatinine, eGFR
Urinalysis (including sediment assessment for erythrocytes, leukocytes, and casts)
Albumin/creatinine ratio
12-lead ECG
Fundoscopy
Pregnancy test in women of reproductive age
Specific tests depending on indications
Troponin, NT-proBNP
Chest roentgenogram
Echocardiography (aortic dissection, heart failure, cardiac ischaemia)
Angio-CT of the chest and/or abdomen (suspected acute aortic syndrome)
Brain CT or MRI (CNS symptoms)
Renal ultrasound (renal dysfunction or suspicion or renal artery stenosis)
Urine toxicology (suspicion of metaamphetamine or cocaine use)
Angio-CT — angiocomputed tomography; CNS — central nervous system; CT — computed tomography; eGFR — estimated glomerular filtration rate; MRI — magnetic resonance imaging; NT-proBNP — N-terminal 
pro B-type natriuretic peptide
Table XXXII. Intravenous antihypertensive medications available in Poland
Urapidil 
Ebrantil 25 — 5 mg/mL (25 mg/5 mL) — 5 mL ampoules
Dosing: bolus 12.5–25 mg iv, followed by iv infusion 5–40 mg/min
Nitroglycerin 
Perlinganit — solution for iv infusion 1 mg/mL (10 mg/10 mL) — 10 mL ampoules
Nitracor — solution for iv infusion 2 mg/mL (10 mg/5 mL) — 5 mL ampoules
Dosing: 5 mg iv, followed by iv infusion 4 mg/h
Esmolol
Esmocard — 100 mg/10 mL — 10 mg/mL (100 mg/10 mL) — 10 mL ampoules
Esmocard — 2500 mg/10 mL — 250 mg/mL (2.5 g/10 mL) — 10 mL ampoules
Dosing: 0.5–1 mg/kg iv, followed by 50–300 mg/kg/min iv
Furosemide
Furosemide Kabi, Furosemidum Polfarmex, Furosemidum Polpharma — 10 mg/mL (20 mg/2 mL) — 2 ml ampoules
Dosing: 20–40 mg iv initially, followed by 20 mg iv every 2 hours as needed; larger doses should be given as iv infusion
In emergencies, labetalol, nicardipine, and sodium nitroprusside may also be given iv but these drugs are currently not available in Poland
iv — intravenous
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 — rapid uncontrolled BP lowering is not recom-
mended due to the risk of complications. The 
recommended drug therapy in specific emergen-
cies is shown in Table XXXIII.
5.17.2. Hypertensive urgencies
In hypertensive urgencies, largely elevated BP is not 
associated with an immediately life-threatening con-
dition. Most patients do not require hospital admis-
sion, but immediate combined oral antihyperten-
sive therapy is needed, and less frequently parenteral 
therapy should be initiated. Hypertensive urgencies 
include conditions associated with antihypertensive 
drug withdrawal or dose reduction, epistaxis, acute 
glomerulonephritis with high BP values, drug-in-
duced hypertension, and hypertension associated 
with spinal cord trauma.
6. Non-blood pressure-lowering therapy 
(treatment of concomitant risk factors) 
in patients with hypertension
6.1. Lipid-lowering drugs
Hypercholesterolemia is more prevalent in hyper-
tensive patients compared to the general population, 
as is atherogenic dyslipidaemia in patients with con-
comitant diabetes. Multiple clinical trials on the use 
of statins in primary and secondary prevention, in 
which hypertensive patients constituted a significant 
proportion of the study populations, indicate that 
an optimal reduction of the global cardiovascular 
risk may be obtained by simultaneous reduction of 
BP and LDL cholesterol level. This particularly justi-
fies use of so-called hybrid SPC, containing both 
a BP-lowering agent and a lipid-lowering agent in 
one tablet. In this context, combinations of two 
antihypertensive agents recommended for treatment 
initiation (e.g., a RAAS inhibitor and a calcium an-
tagonist or a thiazide-type diuretic) with a statin 
seem particularly valuable.
In 2019, new European guidelines may be expect-
ed that will recommend lower target LDL cholester-
ol levels in patients at risk of cardiovascular events, 
including patients with hypertension. Before the 
ESC guidelines will be made available to the public, 
the Polish Cardiac Society Section on Cardiovascu-
lar Pharmacotherapy in 2018 has published their 
Polish recommendations with much lowered target 
LDL cholesterol levels in many patient groups. In 
the present PTNT guidelines, these target values 
are recommended in patients with hypertension 
depending on the level of their cardiovascular risk 
(Tab. XXXIV–XXXVI).
6.2. Antiplatelet therapy
In patients with hypertension and cardiovascular dis-
ease, use of acetylsalicylic acid (ASA) is mandatory 
based on the general guidelines of cardiac societies 
that recommend a 75 mg dose. Use of ASA should 
not be limited by the degree of BP control but is a fac-
tor that makes good BP control particularly necessary.
A recently published large metaanalysis that evalu-
ated the rates of major bleeding events in patients 
receiving long-term ASA treatment has changed the 
approach to the use of this drug in primary pre-
vention. It has been shown that the net benefits of 
ASA, measured as the difference between the car-
Table XXXIII. Recommended drug therapy in specific emergencies
Clinical presentation Timing of BP lowering and therapeutic target First choice drugs Alternative drugs
Malignant hypertension with 
or without acute kidney injury
Reduce MAP by 20–25% 
within several hours Labetalol, nicardipine Sodium nitroprusside, urapidil
Hypertensive encephalopathy Reduce MAP immediately by 20–25% Labetalol, nicardipine Sodium nitroprusside
Acute coronary event Reduce SBP immediately  to < 140 mm Hg Nitroglycerin, labetalol Urapidil
Pulmonary oedema Reduce SBP immediately  to < 140 mm Hg
Sodium nitroprusside or nitrogly-
cerin (with loop diuretic) Urapidil (with loop diuretic)
Acute aortic dissection
Immediately reduce  
SBP to < 120 mm Hg 
and heart rate to < 60 bpm
Esmolol and sodium nitroprusside 
or nitroglycerin or nicardipine Labetalol or metoprolol
Eclampsia or severe preeclampsia, 
HELLP
Immediately reduce 
SBP to < 160 mm Hg 
and DBP to < 105 mm Hg
Labetalol or nicardipine and mag-
nesium sulphate Consider delivery
BP — blood pressure; bpm — beats per minute; DBP — diastolic blood pressure; HELLP — haemolysis, elevated liver enzymes, low platelets; MAP — mean arterial pressure; SBP — systolic blood pressure
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Table XXXIV. Non-blood pressure lowering treatment strategies in patients with hypertension
Assessment of the global cardiovascular risk using the Framingham risk score and the SCORE risk estimation chart (recalibrated nationally as the 
Pol-SCORE risk chart) is recommended in patients with hypertension to determine indications for non-blood pressure lowering treatment
In patients at low cardiovascular risk (no additional risk factors, Pol-SCORE risk < 1%), statin treatment should be considered if LDL cholesterol 
level is > 115 mg/dL
In patients at moderate cardiovascular risk (additional risk factors, Pol-SCORE risk 1–5%), statin treatment, in some cases combined with ezetimibe, 
should be considered to lower LDL cholesterol level to < 100 mg/dL
In patients at high cardiovascular risk (multiple risk factors and/or target organ damage and/or diabetes or Pol-SCORE risk 5–20%), statin treatment, 
in some cases combined with ezetimibe, is recommended to lower LDL cholesterol level to < 70 mg/dL
In patients at very high cardiovascular risk (established cardiovascular disease, including an acute coronary or cerebrovascular event despite LDL 
cholesterol level < 70 mg/dl or Pol-SCORE risk > 20%), maximum tolerated statin dose combined with ezetimibe is recommended to lower LDL 
cholesterol level to < 55 mg/dL
In patients at extremely high cardiovascular risk (multiple cardiovascular events despite LDL cholesterol level < 55 mg/dl), it is recommended to 
add PCSK9 inhibitor therapy to the maximum tolerated statin dose combined with ezetimibe to lower LDL cholesterol level to < 35 mg/dL
Use of allopurinol at the target dose of ≥ 300 mg/d should be considered in hypertensive patients at high cardiovascular risk with asymptomatic 
hyperuricaemia, and even with serum uric acid level > 5–6 mg/dL, despite normal renal function, aiming for the target level of < 5 mg/dL
Use of acetylsalicylic acid 75–150 mg/d or other recommended antiplatelet therapy is recommended for secondary cardiovascular event prevention 
in hypertensive patients regardless of the degree of BP control
Use of acetylsalicylic acid is not recommended for primary prevention in hypertensive patients regardless of the cardiovascular risk level
BP — blood pressure; LDL — low density lipoprotein; PCSK9 — proprotein convertase subtilisin/kexin 9; SCORE — Systematic Coronary Risk Evaluation
Table XXXV. Polish Society of Hypertension guidance on LDL cholesterol level lowering based on the Third Declaration of Sopot
Risk category Clinical condition or presence of risk factors or 10-year Pol-SCORE risk Target LDL  cholesterol level
Low No additional risk factors < 115 mg/dL (< 3.0 mmol/L)
Moderate < 2 risk factors and Pol-SCORE risk < 5% < 100 mg/dL (< 2.6 mmol/L)
High ≥ 2 risk factors and Pol-SCORE risk 5–20%Diabetes or stage 3–4 CKD with no other risk factors
< 70 mg/dL 
(< 1.8 mmol/L)
Very high
Progression of atherosclerotic cardiovascular disease in patients in whom LDL cholesterol level 
< 70 mg/dL was achieved and maintained
Acute coronary syndrome, coronary artery disease, carotid artery disease or peripheral arterial 
disease
Previous revascularization
Pol-SCORE risk > 20%
Diabetes or stage 3–4 CKD with 1 or more other risk factors
Familial hypercholesterolaemia
Family history of premature atherosclerotic cardiovascular disease (< 55 years in men, < 65 years 
in women)
Established cardiovascular disease in patients with diabetes, stage 3–4 CKD or familial hyperchole-
sterolaemia
< 55 mg/dL 
(< 1.4 mmol/L)
Extremely 
high
Multiple previous cardiovascular events and/or revascularizations
Percutaneous revascularization at specific anatomical locations (e.g., patients after percutaneous 
revascularization for left main coronary artery disease and/or with multivessel coronary artery 
disease)
Generalized atherosclerosis — involvement of multiple vascular beds with additional risk factors
Progression of atherosclerotic cardiovascular disease in patients in whom LDL cholesterol level 
< 55 mg/dL was achieved and maintained
< 35 mg/dL 
(< 0.9 mmol/L)
CKD — chronic kidney disease; LDL — low density lipoprotein; SCORE — Systematic Coronary Risk Evaluation
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diovascular event rate reduction and the increase in 
the major bleeding event rate, have not been clearly 
established in this patient population. Until now, use 
of ASA for this indication required evaluation of the 
risk-to-benefit ratio. In the current 2018 ESC/ESH 
guidelines, use of ASA for primary prevention of 
cardiovascular events is not recommended. In view of 
this abandonment of ASA for primary prevention in 
hypertensive patients at high cardiovascular risk, use 
of alternative substances with antiaggregant proper-
ties that have been evaluated in clinical trials (e.g., 
standardised tomato extract which exerts a weaker 
antiplatelet effect compared to ASA but has a more 
pleiotropic activity range) may be considered.
6.3. Uric acid-lowering therapy
In the 2018 ESC/ESH guidelines, elevated uric acid 
level has been considered a novel significant cardio-
vascular risk factor in patients with hypertension. 
A similar position has been taken in the present 
document. Uric acid production in the setting of 
ischaemia is associated with free radical formation 
and endothelial dysfunction. It has been shown 
that use of xanthine oxidase inhibitor allopurinol 
leads to improved endothelial function and aortic 
compliance, and the result of more recent stud-
ies indicate a reduction of the cardiovascular event 
risk, particularly with allopurinol dose of 300 mg/d. 
For this reason, following the international expert 
consensus statement, the present PTNT guidelines 
recommend consideration of allopurinol use in hy-
pertensive patients at high cardiovascular risk if  uric 
acid level is elevated (> 5–6 mg/dL) despite normal 
renal function.
Table XXXVI. Polish Society of Hypertension guidance on the use of lipid-lowering drugs based on the Third Declaration of Sopot
Risk category Use of lipid-lowering drugs Target  LDL cholesterol level
Low Low-dose statin < 115 mg/dL (< 3.0 mmol/L)
Moderate Moderate-dose statin < 100 mg/dL (< 2.6 mmol/L)
High Moderate- to high-dose statinEzetimibe 
< 70 mg/dL 
(< 1.8 mmol/L)
Very high High-dose statinEzetimibe
< 55 mg/dL 
(< 1.4 mmol/L)
Extremely high
High-dose statin
Ezetimibe
PCSK9 inhibitor
< 35 mg/dL 
(< 0.9 mmol/L)
LDL — low density lipoprotein; PCSK9 — proprotein convertase subtilisin/kexin 9; SCORE — Systematic Coronary Risk Evaluation
7. Methods to improve blood pressure 
control in hypertensive patients
Published studies indicate that many hypertensives 
are unaware of their elevated BP values, and even 
if they are aware of their hypertension, many in-
dividuals remain untreated. In addition, target BP 
levels are infrequently reached regardless of whether 
the treatment is undertaken by specialists or general 
practitioners. At the same time, the proportion of 
patients aware of their hypertension and the need to 
control elevated BP increases slowly and this trend is 
seen only in some patients, mostly in the secondary 
prevention population. It is currently believed that 
providing patients with easily comprehensible edu-
cational materials distributed by media or available 
in physician offices and pharmacies has a beneficial 
effect of patient knowledge and motivation.
In clinical practice, two major causes of poor BP 
control may be identified:
1. Poor patient compliance.
2. Therapeutic inertia.
Non-compliant patients may be divided into those 
who permanently discontinue the therapy and those 
who use their medications in an inappropriate way 
(e.g., irregular drug intake, including delayed dosing 
and multiple short-lasting treatment interruptions). 
Poor patient compliance is also a very frequent prob-
lem in regard to the recommended lifestyle changes. 
Regarding use of prescribed medications, studies in-
dicate that more than one third of patients discon-
tinue antihypertensive drug therapy by 6 months, 
and about half of patients discontinue it by one year. 
In addition, about 10% of patient forget to take their 
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medication on any given day. For this reason, efforts 
to increase patients’ compliance and persistence are 
a duty of the treating physician. Studies indicate that 
the elderly patients are more motivated to treatment. 
However, they are characterised by greater persistence 
but lower compliance compared to younger subjects. 
Some of the causes of low patient-physician coop-
eration worsen in the elderly age, including memory 
problems, difficulties with understanding the dosing 
regimen, worse tolerance of normal BP values, finan-
cial problems with prescription filling, concomitant 
disease giving rise to more troubling complaints, 
and the need to take multiple medications. Patients, 
particularly the elderly, require time to be taken to 
explain the dosing regimen and the importance of 
antihypertensive treatment, and sometimes engage 
the family members or enquire about the financial 
situation of the patients. Two of the changes in the 
management of hypertension highlighted in the pres-
ent guidelines may improve compliance. Somewhat 
higher target BP values in the elderly may improve 
treatment tolerance and mitigate the effect of treat-
ment on quality of life in this patient group. The role 
of SPC in the antihypertensive therapy has increased, 
and with a decreased number of tables and simplified 
dosing regimens, it may be possible to both increase 
compliance and decrease therapeutic inertia, or no 
treatment intensification by the physician despite 
inadequate BP control in the patient. Increased use 
of SPC may be facilitated by wide reimbursement of 
this treatment for indications discussed in the present 
guidelines.
